https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/celldex-reports-positive-phase-3-results-for-barzolvolimab-in-chronic-spontaneou-0017f5ea9d432ed0 2026-09-22T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bofa-securities-names-top-biotech-stock-amid-sector-rally-65a732f8b3124bfc 2026-09-22T10:56:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-merck-drug-cut-the-risk-of-worsening-disease-by-76-the-fda-updated-its-label-35639d1ef2653d3e 2026-09-22T10:50:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-phenylephrine-hydrochloride-prices-hold-firm-as-q4-pharmaceutical-demand-stre-0149dcbbdb4b1dc3 2026-09-22T10:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-approves-update-to-the-label-for-winrevairtm-sotatercept-csrk-to-include-d63bea0d0db63aa3 2026-09-22T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trials-for-medicines-good-clinical-practice-inspections-68a2c21adf64b7b1 2026-09-22T10:42:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-f39731160de90db0 2026-09-22T10:37:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-admet-ai-for-medicines-safety-survey-a86c0a5b77beeed2 2026-09-22T10:00:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/harmoni-gi1-a-phase-iii-trial-featuring-ivonescimab-plus-chemotherapy-compared-t-5397d986a24a195a 2026-09-22T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/direct-nitrite-analysis-simplifies-tests-of-pharmaceutical-excipients-for-risk-c-4b362d430ed610ea 2026-09-22T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regulatory-round-up-22-september-2026-5ba9abe7a8a91f88 2026-09-22T09:23:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/mannkind-corporation-mnkd-stock-analysis-exploring-a-127-68-potential-upside-in-88d42183e45cec68 2026-09-22T09:21:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/book-review-the-age-of-cures-by-barry-werth-50b9ec628976b5a2 2026-09-22T09:00:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-signs-277-mil-taxotere-supply-deal-with-china-s-yifan-6f397d63d69e2daf 2026-09-22T08:37:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/reg-hikma-pharmaceutical-director-pdmr-shareholding-bb695b3e1242f838 2026-09-22T08:32:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-and-university-of-oxford-scientists-uncover-genetic-changes-in-the-bacteri-619305ae10369373 2026-09-22T08:30:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/voluntary-scheme-aggregate-net-sales-and-payment-information-august-2026-1002643f3a56701e 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-health-impacts-from-industrial-sources-of-pfas-a-rapid-review-ed4c661ce7265e41 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/per-and-polyfluoroalkyl-substances-pfas-general-information-49da969af76edf3b 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/vpag-quarterly-net-sales-and-payment-information-e87d48f3b7220662 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemical-hazards-compendium-2cf1a7b32dba1e24 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanyang-precision-chairman-countersues-former-hanmi-pharmaceutical-executives-29f8aa0fd33812f7 2026-09-22T08:20:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/submicron-ir-for-pharmaceutical-research-development-and-quality-f91eaac67fdb6ecb 2026-09-22T07:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sant-98561788d726bcd6 2026-09-22T07:40:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-s-2026-single-trial-default-standard-reframes-the-dual-pivotal-debate-for-sp-db564c899dadd3aa 2026-09-22T07:35:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/greece-to-prioritise-biosimilars-legislation-during-2027-eu-presidency-says-mini-7c952cb632ab6e86 2026-09-22T07:33:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/mayer-brown-represents-underwriters-on-teva-pharmaceutical-s-us-4-9-billion-seni-c8c0fec7c979c997 2026-09-22T07:28:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/iambic-maintains-momentum-from-string-of-big-pharma-partnerships-by-aiming-for-i-14246701c70fe37f 2026-09-22T07:14:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/trevi-therapeutics-stock-trades-at-usd-14-71-as-biotech-data-matters-663f1d5418a1fc34 2026-09-22T07:13:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-aspen-s-priyen-naidu-drives-a-human-centred-approach-to-technology-f2ab4450d8792b6a 2026-09-22T07:10:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/bank-of-america-corp-de-invests-38-35-million-in-ultragenyx-pharmaceutical-inc-r-127cbc20e446c4bf 2026-09-22T07:10:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/building-on-success-ipsen-receives-two-new-gold-brandon-hall-awards-d9486765e1c17bb8 2026-09-22T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merry-life-biomedical-starts-phase-2-trial-of-tml-6-for-early-alzheimer-s-045429441a897961 2026-09-22T06:45:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/ec-approves-obicetrapib-as-oral-cetp-inhibitor-for-hypercholesterolemia-ae296af74503e57a 2026-09-22T06:40:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biolog-b7cd7818b37e9411 2026-09-22T06:05:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-cadbbf2157ab9b29 2026-09-22T06:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-biotech-self-reliance-moment-102921bdf8bc7232 2026-09-22T05:50:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-best-glp-1-stocks-for-2026-and-how-to-invest-99408731658b95c2 2026-09-22T05:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-scores-277m-anti-cancer-drug-supply-deal-in-china-d65692bc15e5f4fc 2026-09-22T05:02:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-announces-positive-phase-ii-resu-ca3349841e8c60a5 2026-09-22T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/healthnet-mea-to-commercialise-comide-er-methylphenidate-er-in-uae-under-exclusi-25f7252f14d192bd 2026-09-22T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/child-resistant-locking-closures-market-to-2035-pharmaceutical-safety-mandates-d-ee831d2ecb1081b6 2026-09-22T04:46:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-news-96d7107e3a341182 2026-09-22T04:26:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-478bd63e265078d4 2026-09-22T03:35:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-moves-away-from-animal-testing-how-organoids-ai-organs-on-chips-could-imp-8ae12dc92c9fbd34 2026-09-22T03:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-signs-277-million-taxotere-supply-deal-with-china-s-yifan-pharmaceutical-a71b4ed4f2241099 2026-09-22T03:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/melbourne-biotech-turns-to-stem-cell-brain-models-in-alzheimer-s-push-7ea3ae37b3c8e127 2026-09-22T02:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-strict-checks-on-drug-supply-chain-9e99b919fddbd074 2026-09-22T02:29:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524 2026-09-22T01:59:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-s-breast-cancer-combo-wins-approval-2625666fc10dfe92 2026-09-22T01:26:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-ultragenyx-pha-eb82ae5a7d95e0ef 2026-09-22T01:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-envista-holdin-90aff1940631b27a 2026-09-22T01:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-wellbeing-and-boryung-expand-korea-hospital-use-of-livnec-injection-chosunbiz-f8357be306326357 2026-09-22T00:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-details-phase-3-sleep-apnea-trial-for-ex-metsera-obesity-drug-9b66bc3b08304ba5 2026-09-22T00:38:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-4fd90a4772882d47 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-fd60ec54e19ca4dd 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-ed2de6da22997440 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-3e5f82e39c8b8bf4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-f7927690eb466ad3 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-a7ab313d50b6dd5c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a40a0eff36af50dd 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-0aa0ed7c37800ffb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-4fa3fa5cb8800304 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-98e36b23d5995f81 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-b18316af92c7180d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-92339e3d32b05f49 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-9f39f62d36b861e7 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-ec6a264c379d0165 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-cancer-institute-notice-of-meeting-8918f24bc0866cb9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-e3d513e458366039 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-774090bba85bb2af 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nonclinical-testing-terminology-5eba25885ce1826a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-c3c6da23622a87ae 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-the-impact-and-costs-of-promoti-1981b0d77e209b56 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-ed0ae1132b37b44c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-meeting-request-fo-9ec32231184cff8d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/summary-for-patients-tobacco-use-treatment-synopsis-of-the-2026-u-s-department-o-07d3fe471f477728 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hybrid-endoscopic-submucosal-dissection-enhances-efficiency-with-comparable-cura-59f35ebeba6339bc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advances-risks-and-implementation-challenges-of-artificial-intelligence-as-a-for-0aaebc5fc67cb1f4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/to-what-extent-is-water-hydration-the-best-method-of-maintaining-voice-protectio-c0b14f3feb98d6fc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/design-and-limitations-of-tumor-microenvironment-responsive-nanocarriers-for-tar-a541e35ac2a228eb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ethical-legal-and-societal-implications-in-xenotransplantation-elsi-a-korean-reg-574b7c8e38dc1ea4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/practicing-in-resource-limited-and-siloed-settings-b8a360d6cc716831 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synbiotic-hqp08-supplementation-for-hair-loss-and-depressive-symptoms-an-open-la-d810c0348c9d2a53 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-participatory-strategies-for-prevention-of-dengue-and-leptospir-8b622e47d75a3a2e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-cardiotoxicity-in-pediatric-patients-with-acute-lymphoblastic-leukemia-and-66bd0483b1ad137d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-tumour-biology-into-surgical-decision-making-for-metastatic-colorect-72069f85a27f2b65 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/asparagine-synthetase-deficiency-a-novel-asns-variant-and-a-systematic-review-of-7688496f64879380 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/economic-evaluation-of-primary-health-care-integration-and-targeted-mass-drug-ad-23f6f417faae079e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-following-a-traditional-chinese-medicine-foot-bath-preparation-71dccefa5ac0c66e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-post-procedural-parenteral-anticoagulation-therapy-and-clini-aa105c9902a1b506 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/thromboembolic-prophylaxis-in-childhood-idiopathic-nephrotic-syndrome-from-patho-561cd01380060c71 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultrasound-defined-fatty-liver-and-the-risk-of-progression-from-preclinical-to-c-f9a84b6d726a3f6e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hematoma-expansion-in-intracerebral-hemorrhage-neuroimaging-biomarkers-radiomics-e09c758c16081ca4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-non-invasive-brain-stimulation-from-basic-science-to-clinical-applicat-57c6e566091c722c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-fracture-stabilization-to-functional-recovery-a-prospective-clinical-radiol-b0de384d30fed29f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-radiological-outcomes-after-philos-locking-plate-fixa-tion-of-proxi-6cb1d9db4ee8d196 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/magnetic-resonance-imaging-evaluation-of-oblique-injuries-introduction-of-the-de-8fc08014efbffe9e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-reproducible-framework-for-auditing-the-trustworthiness-of-clinical-machine-le-e156ce2fb89f21be 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-statistical-similarity-a-clinical-validation-framework-for-synthetic-acut-72e3848e5ab24c81 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-association-between-clinical-activity-and-inflammatory-response-in-odontogen-bd41993f007c7d9a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-lean-beef-on-resistance-training-induced-strength-and-body-compositio-7dbccd69d52aea28 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antioxidant-premedication-reduces-mitochondrial-and-nuclear-dna-damage-repair-in-cecfc8008ef47d6f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ct-derived-myocardial-extracellular-volume-current-evidence-clinical-utility-and-f91615e1f0f6a045 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-phosphate-supplementation-after-newly-detected-hypophosphatemia-in-older-i-5ee50f7a22451580 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/associations-between-social-determinants-of-health-and-clinical-diagnosis-time-o-ba252f64579ea133 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-stroke-crisis-in-ageing-societies-global-trends-risk-factors-and-clinical-va-eebc145ad0ea6bea 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/response-by-maurer-and-fontana-to-letter-regarding-article-coramitug-a-humanized-b092e4d1b40d77b4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-3-dual-single-pill-combinations-for-blood-pressure-lowering-a-seco-934d9095d9196874 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychological-pathways-from-disease-activity-to-quality-of-life-in-ulcerative-co-0133cc63b78f7bb5 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/my-unbearable-wife-gave-me-a-brain-tumor-subjective-theories-of-illness-and-reco-d9c4caf1f4a588e9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-therapists-need-to-be-their-own-clients-the-influence-of-intersectional-pri-12d08479260be075 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/contributions-of-semiotic-cultural-psychology-for-interventions-in-clinical-psyc-cf12230181a710fb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-literacy-antibiotic-use-behaviors-and-awareness-of-antimicrobial-resistan-7a7abb1fc6fe4ec9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-introducing-automated-plan-checking-in-radiation-therapy-effe-220fbd73db8233f8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-effectiveness-safety-and-tolerability-of-ozenoxacin-2-lotion-vs-clind-75efa1fd26813f4c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bacterial-outer-membrane-vesicles-in-colorectal-cancer-interdomain-communication-95e0d6534503eb25 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-early-systolic-blood-pressure-and-clinical-outcomes-in-non-c-69ae09590efea90e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-combined-repetitive-transcranial-magnetic-stimulation-and-occupation-b74d503d8324ad1e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacovigilance-practices-educational-interventions-and-barriers-to-reporting-535468794e77582d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/occupational-allergies-clinical-presentation-epidemiology-diagnosis-and-preventi-d3e45acd9d403f28 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-conceptual-disease-model-of-atopic-dermatitis-using-data-from-t-b724371d717c237f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anti-tnf-refractory-inflammatory-bowel-disease-associated-with-a-novel-xiap-fram-b48dd066032a9779 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-cuprous-oxide-nanoparticles-green-synthesized-using-artemisia-dracuncu-cc51fb0cd6ece9b8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-evaluation-of-a-hydroxyurea-loaded-invasome-hydrogel-for-enhance-994c6bdc360fa4cc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/photocatalytic-treatment-of-organic-and-pharmaceutical-pollutants-in-wastewater-fb6ba995d39dc801 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tissue-specific-aging-clocks-map-structured-aging-modulatory-drug-score-patterns-9b721b6fd4c871b6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-accuracy-amp-clinical-importance-of-ai-confidence-for-extremity-fract-cf31f9fe3c4a8ca6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/could-previous-appendicectomy-influence-disease-expression-in-axial-spondyloarth-e9e0c066f4387e8f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-performance-of-glass-hybrid-and-short-fiber-reinforced-composite-restor-651b546e41d9bbe2 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-interchangeability-of-22c3-and-28-8-pd-l1-assays-for-patient-selection-343e8ac84fe0cb4f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/glaucoma-in-hospitalized-older-adults-polypharmacy-multimorbidity-and-therapy-di-fbced7d96caeaf15 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/specific-treatment-of-attr-cm-in-germany-expert-consensus-of-the-german-society-4b5e24406ecb15a6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regimen-stratified-bayesian-model-based-meta-analysis-of-targeted-biologics-in-g-760b3481681182f4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/measuring-what-vlms-don-t-say-validation-metrics-hide-clinical-terminology-erasu-ad6cc70c31430f76 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/circulating-blood-biomarkers-after-traumatic-brain-injury-a-subanalysis-of-the-b-62e62e5a6d913481 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amcham-imss-deal-pledges-us-44-million-to-bring-clinical-trials-to-mexican-publi-052095dbcfb7da9a 2026-09-21T23:39:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/nice-recommends-enhertu-for-her2-low-advanced-breast-cancer-in-england-9d334852ef112a45 2026-09-21T22:50:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/drummond-warns-rubio-of-national-security-risk-in-pharmaceutical-supply-chain-5a65cb2ace796337 2026-09-21T22:48:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-rulemaking-chatter-lifts-hong-kong-s-china-biotech-names-4fcfe264207382d9 2026-09-21T22:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-6bcac29ff06fe76b 2026-09-21T21:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-companies-push-trump-administration-to-protect-china-deals-40671ca1388c0776 2026-09-21T21:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-logistics-market-to-reach-usd-194-0-billion-by-2034-at-7-7-cagr-d-405b29a18e79aec5 2026-09-21T21:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-and-leveraged-etfs-lead-market-d-9c02833c76771b58 2026-09-21T21:28:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-houston-plant-078eb0965183eec9 2026-09-21T21:21:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/dompe-settlement-highlights-doj-continued-scrutiny-of-pharmaceutical-manufacture-433de672942d089b 2026-09-21T21:15:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/iam-ipo-news-small-molecule-biotech-iambic-therapeutics-files-for-a-100-million-3bc12612e27dfbee 2026-09-21T21:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-pharmaceutical-factory-in-houston-2f381a479b3555a2 2026-09-21T20:58:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/screening-china-origin-biotech-ip-a-new-u-s-eu-divide-fe79769761ea8dd8 2026-09-21T20:45:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-4b5e30b480cbde92 2026-09-21T20:38:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicus-pfizer-deal-was-not-a-fire-sale-a-strategic-bet-on-de-risked-adc-drug-8e03cd57f1797c93 2026-09-21T20:35:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/buerger-s-disease-clinical-trial-pipeline-gains-momentum-3-91e1bc0bbb6b2bea 2026-09-21T20:24:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-glp-1-shortage-is-over-mass-market-compounding-should-be-too-5d8cd6869a85189b 2026-09-21T20:06:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-connected-peninsula-company-plots-ipo-as-it-takes-on-eczema-and-more-0871b8e09373ffce 2026-09-21T19:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/par-health-issues-voluntary-nationwide-recall-of-two-lots-of-dexmedetomidine-hcl-488b45799ea71d6a 2026-09-21T19:37:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/positive-topline-phase-3-study-results-lumateperone-for-manic-episodes-in-bipola-ea5127591948df34 2026-09-21T19:34:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-why-is-it-back-in-the-spotlight-feca7b108b11fdaf 2026-09-21T19:11:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/cphi-milan-leadership-summit-returns-with-supply-chain-focus-543b72ef7ec0a6e6 2026-09-21T19:06:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/faq-how-the-generous-model-applies-mfn-pricing-to-medicaid-3108639fbd284b85 2026-09-21T19:04:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-analyses-of-hlp003-for-the-adjunctive-treatment-of-mdd-610c32551287df6e 2026-09-21T19:04:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-icu-medical-llc-issues-voluntary-nationwide-recall-of-0-9-sodium-chloride-61a649d42d701917 2026-09-21T19:00:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-forms-ai-powered-drug-discovery-partnership-with-iambic-pharmexec-7df1eac9f5ddbb27 2026-09-21T18:57:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-regulations-to-expand-alternatives-to-animal-testing-in-drug-develop-0ab1dcb84feb442a 2026-09-21T18:33:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/s2s-china-selects-10-biotech-finalists-to-pitch-global-investors-at-westlake-uni-cc798694b80a8b1b 2026-09-21T18:33:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/sec-fda-information-sharing-mou-implications-for-pharma-and-biotech-f12ad8cd85d5f095 2026-09-21T18:24:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmosa-biopharm-s-inhaled-drug-l608-wins-fda-approval-for-phase-2-trial-shares-623a9af03fd0b72d 2026-09-21T18:23:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/life-sciences-real-estate-trends-what-to-expect-3bd7b4d3a44b9c76 2026-09-21T18:05:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-watch-and-pharma-industry-news-72f24107382921a8 2026-09-21T17:49:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing-895b941874bc4068 2026-09-21T17:14:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugs-racket-kingpin-s-pharmacy-stayed-open-after-raid-health-officer-suspended-710aba0a714d4a51 2026-09-21T17:14:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-developer-adarx-seeks-1-74-billion-valuation-in-us-ipo-da6c89fec62607a7 2026-09-21T16:55:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574 2026-09-21T16:20:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/xenetic-to-acquire-santersus-in-net-targeting-biotech-combination-ec88c0dae17857a4 2026-09-21T16:15:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-recalls-and-warnings-third-glutathione-recall-issued-over-endotoxin-contamin-07b548b075a272fe 2026-09-21T16:12:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-etfs-to-buy-as-cancer-drug-breakthroughs-accelerate-bd41f997cae1257c 2026-09-21T16:03:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bengaluru-assistant-drug-controller-suspended-in-counterfeit-drug-case-3638b689e7e0c3d9 2026-09-21T15:50:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-commission-approves-roche-s-susvimo-for-the-treatment-of-neovascular-ag-5503298c000d9a8a 2026-09-21T15:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-surges-9-as-phase-3-melanoma-data-wins-presidential-symposium-slot-merck-3da8f65777798006 2026-09-21T15:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-of-my-top-small-cap-biotech-picks-made-a-move-here-s-how-i-trade-it-6eb55c5568c32d22 2026-09-21T15:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bmy-vs-gild-which-biotech-stock-looks-more-attractive-now-6c620882c75be90d 2026-09-21T15:08:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-top-7-atypical-psychedelics-a-brief-clinical-guide-3d93abb04fc90f32 2026-09-21T15:06:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-roundup-on-the-cannabis-sector-psychedelic-sector-a4229cf49083a849 2026-09-21T15:01:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/bytedance-baidu-hengrui-novo-nordisk-driving-breakthroughs-in-ai-pharmaceutical-fbcbc6c19d988c7c 2026-09-21T15:01:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-and-biotech-industry-audit-services-for-gmp-gxp-and-supplier-compliance-2ecc2a1cefcf64f8 2026-09-21T14:58:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-fda-wants-pro-life-states-to-keep-waiting-b6f6153c4948a5f2 2026-09-21T14:57:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cspc-pharmaceutical-group-sehk-1093-expands-its-pipeline-is-the-stock-still-unde-873fbda566f6532f 2026-09-21T14:52:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/lakewood-amedex-announces-irb-approval-and-clinical-site-readiness-to-initiate-p-2dfc2ee296889841 2026-09-21T14:45:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/plug-and-play-seattle-picks-11-startups-for-4th-cohort-from-space-robotics-to-bi-a4ef32ff512f3201 2026-09-21T14:42:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/beijing-unveils-blueprint-for-biomedical-dominance-by-2030-d2e6d08e6ff0538c 2026-09-21T14:41:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/concord-biotech-bonus-issue-sparks-rally-pharma-stock-jumps-6-on-maiden-share-re-3ca3b429b4874d3e 2026-09-21T14:28:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/evita-clinical-trial-evaluates-oral-vitamin-c-for-pre-cancerous-blood-disorders-8e446074c31c386e 2026-09-21T14:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-ac0ba1a6f705851f 2026-09-21T13:59:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-regulations-to-advance-alternatives-to-animal-testing-efae5931c8e859cd 2026-09-21T13:45:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-veterinarios-de-septiembre-de-2026-224e8a08e13866ca 2026-09-21T13:44:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cancels-16-drug-licences-suspended-08-others-in-connection-with-alleged-dist-51785b064dcf2ded 2026-09-21T13:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/eu-pharma-reform-strategic-implications-for-us-drugmakers-8f7f8ee4ad186bb7 2026-09-21T13:27:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-targets-25-share-of-global-first-in-class-drugs-in-new-5-year-plan-0e7df4b725539007 2026-09-21T13:12:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-stock-price-expected-to-rise-barclays-anal-81130dfa0ccc6837 2026-09-21T13:05:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7 2026-09-21T13:00:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-new-cholesterol-drugs-get-their-first-global-approval-in-europe-61a68e250907fc8e 2026-09-21T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-opens-expedited-drug-trial-pilot-to-cut-development-delays-f3806e23c82077de 2026-09-21T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dc 2026-09-21T12:59:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/telix-tlx-lines-up-us-1-65b-cancer-drug-merger-and-a-big-revenue-jump-8adff125aee08116 2026-09-21T12:56:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/adrx-ipo-news-sirna-biotech-adarx-pharmaceuticals-sets-terms-for-350-million-ipo-7c6df0ecf3d07353 2026-09-21T12:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-inc-bofa-global-research-raises-price-objective-to-400-from-392-76033b6bd017aee9 2026-09-21T12:46:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-china-biotech-licensing-expected-to-thrive-as-washington-softens-stance-news-7bfa8d1d5a5b74b0 2026-09-21T12:40:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/bofa-adjusts-price-target-on-krystal-biotech-to-400-from-392-keeps-buy-rating-3e1641c6da3c6b68 2026-09-21T12:34:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/factbox-weight-loss-drug-developers-line-up-to-tap-lucrative-market-as-competiti-5514ab11a1196d72 2026-09-21T12:28:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/rhelion-subsidiary-supplies-psilocybin-for-phase-3-palliative-care-trial-0d4d220a9ee9c49e 2026-09-21T12:11:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/denmark-eyes-shortage-substitution-protocols-as-industry-urges-tight-limits-d1dc310ade3ee8de 2026-09-21T12:10:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/covid-19-vaccine-5-years-and-over-pgd-and-vgd-6776102a716b3a92 2026-09-21T12:10:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/arch-biopartners-under-pressure-clinical-stage-biotech-faces-renewed-selling-as-327b8f6542f8321e 2026-09-21T12:09:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-targets-25-of-global-first-in-class-drugs-by-2030-in-new-pharma-five-year-f8d103925f821267 2026-09-21T12:06:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-2-trial-suggests-vitamin-c-may-benefit-people-with-pre-cancer-blood-disord-64b38f62af9ca22e 2026-09-21T12:05:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/filament-ships-psilocybin-drug-pex010-for-phase-3-trial-on-psychological-distres-00504eb35086a553 2026-09-21T12:03:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/weight-loss-drug-developers-line-up-to-tap-lucrative-market-as-competition-heats-54efba15b344cc0f 2026-09-21T12:01:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-c-f-depot-licence-suspended-as-karnataka-probes-fake-drug-racket-eb671632b4449c57 2026-09-21T12:01:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-14963d1b5f3d3bc5 2026-09-21T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-s-drug-price-plan-targets-foreign-freeloaders-but-shoots-american-innovato-5e14093c8aaa4a87 2026-09-21T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-6b060a185e233d47 2026-09-21T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psilocybin-doses-without-hallucinations-will-be-tested-in-end-of-life-care-6c1213d2afac37ae 2026-09-21T11:49:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/virtual-biotech-employs-37-000-ai-agents-for-end-to-end-drug-development-8f7d97a93a576cdc 2026-09-21T11:46:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/cyllene-appoints-seasoned-biotech-exec-as-cfo-74f91b753010fd2c 2026-09-21T11:40:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-exports-continue-to-strengthen-the-swedish-economy-6d1e9ae333cb8b5f 2026-09-21T11:37:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-ema-y-hma-abren-el-proceso-de-comentarios-sobre-la-nueva-guia-de-eu-in-para-i-b9a7929b040a0936 2026-09-21T11:26:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-minister-says-pfizer-c-f-agency-failed-to-aid-fake-drug-probe-d544ad166f836728 2026-09-21T11:23:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-community-based-scale-up-of-integrated-community-health-worker-le-05286051f35c02ca 2026-09-21T11:22:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-microwave-photonics-platform-for-cancer-detection-and-treatment-4e2c58f5b234309a 2026-09-21T11:22:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-the-interaction-between-chronic-pain-and-genetics-in-contributing-5d67fb178fa044ee 2026-09-21T11:22:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-towards-predictive-computational-platform-for-drug-solubilization-1268e26242a4e7b4 2026-09-21T11:22:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-controlling-reactive-species-delivery-in-cold-plasma-jets-a-key-c-7546c6a43992920d 2026-09-21T11:22:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-electrochemical-carboxylic-acid-exchange-for-sustainable-drug-dev-e80014a705f27d3b 2026-09-21T11:22:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/brazil-pharmaceutical-distributors-face-mounting-financial-pressure-2eeef9a7b9aca460 2026-09-21T11:20:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/sichuan-biokin-pharmaceutical-s-unit-receives-milestone-payment-from-bristol-mye-ca99112d5b22276b 2026-09-21T11:16:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychedelics-are-wall-street-s-next-trip-why-this-biotech-stock-is-already-up-20-52049d1cb6186539 2026-09-21T11:08:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/alkermes-orexin-agonist-shows-potential-to-treat-adhd-in-early-stage-trial-7d805f10ecf38946 2026-09-21T11:03:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-4e3af3cef35b6b21 2026-09-21T11:02:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-993c912068e3ffbe 2026-09-21T11:02:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/tiziana-announces-last-patient-completes-last-visit-in-phase-2a-inform-ms-trial-121aeb1f6cd0e04c 2026-09-21T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alkermes-announces-positive-phase-1b-results-demonstrating-clinical-proof-of-con-e143bd6657dbae3b 2026-09-21T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-inline-refractive-index-monitoring-can-improve-real-time-peptide-manufacturi-6daaaf2be2a7405b 2026-09-21T10:54:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/singapore-draws-international-biotech-vcs-as-asia-pacific-life-sciences-sector-t-8b267d226e97ee94 2026-09-21T10:53:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-co-ltd-to-go-ex-dividend-on-september-22nd-2026-with-7e95578a30c6b612 2026-09-21T10:48:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-s-keytruda-qlextm-pembrolizumab-and-berahyaluronidase-alfa-pmph-approved-i-cb6eee590ac0416c 2026-09-21T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-nyse-teva-legal-chief-files-273k-share-sale-notice-e62f1c4bffd47859 2026-09-21T10:40:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/tekpac-s-intelligent-packaging-increases-output-for-patch-manufacturer-5fc87af611260110 2026-09-21T10:30:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-fda-has-approved-29-u-k-led-cancer-drugs-since-2021-now-a-u-k-regulator-will-a64efa1f5f19d8b7 2026-09-21T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/os-therapies-completes-fda-type-c-statistical-methods-meeting-and-provides-updat-79fead0c1f7c2adf 2026-09-21T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-secures-full-fda-nod-for-inluriyo-verzenio-breast-cancer-combo-986279ff4c2ee3b2 2026-09-21T10:29:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-buys-three-non-incretin-obesity-programs-from-kallyope-1771b5edb75f4697 2026-09-21T10:29:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-aug-16bd5e27d65a23b1 2026-09-21T10:28:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-2a4014b9e82727c7 2026-09-21T10:28:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/major-reform-of-eu-drug-regulations-what-will-change-for-patients-1b494b7bc3bbb314 2026-09-21T10:25:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/metavallon-backs-parkinson-s-biotech-anacalypsis-in-first-of-its-kind-greek-deal-a0596c80e643d916 2026-09-21T10:14:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/research-collaboration-to-advance-a-novel-therapy-for-alzheimer-s-disease-f02f2d6a6aefabfc 2026-09-21T10:09:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-busts-fake-drug-racket-pfizer-depot-7-other-firms-face-licence-suspens-3be6e17a0c46130a 2026-09-21T10:09:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-treasury-reportedly-drafting-rules-to-preserve-pharma-licensing-deals-with-ch-267bf55a61b7fc6a 2026-09-21T10:06:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/xenon-stock-craters-30-on-drug-trial-setback-its-failure-could-be-this-biotech-s-56a2fa84d3bb02c3 2026-09-21T10:03:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/cannabinoids-vs-opioids-is-chronic-pain-treatment-at-a-turning-point-6360efc5a5b20214 2026-09-21T10:00:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-tide-of-china-biotech-deals-seen-as-us-curb-fears-fade-analysts-aaba7a319c133b2c 2026-09-21T10:00:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-finance-report-england-2025-to-2026-edfdf55f46596236 2026-09-21T09:52:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-activity-report-england-2025-to-2026-d04cfc1369caa66d 2026-09-21T09:52:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-43-report-data-to-week-42-dat-99cbb355a95c8f35 2026-09-21T09:51:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-18-october-2026-673a62d4be0d46e6 2026-09-21T09:51:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-43-report-data-to-week-42-data-up-t-d32e68d6017bb7c3 2026-09-21T09:51:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/cold-mortality-monitoring-report-england-winter-2025-to-2026-625b82782f2a1916 2026-09-21T09:51:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-39-report-data-to-week-38-data-up-t-b701a0f0114ed05c 2026-09-21T09:50:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/d-d-pharmatech-s-head-of-r-d-park-eun-ji-newco-bridges-early-stage-biotech-firms-b72d729bb82a03d9 2026-09-21T09:45:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/belgium-s-novadip-biosciences-raises-10-4-million-to-fund-pivotal-clinical-trial-1c00f7f63d3d96ab 2026-09-21T09:40:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/thousands-invited-to-register-for-public-panel-for-independent-commission-on-adu-52b360f1b8267410 2026-09-21T09:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/3-chinese-biopharma-stocks-retail-investors-are-watching-for-licensing-deals-f9c5948024fb39f8 2026-09-21T09:24:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-ultragenyx-pharmaceutical-inc-nasdaq-rare-is-in-focus-now-2794a473faf0e70f 2026-09-21T09:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sarepta-therapeutics-srpt-stock-analysis-navigating-the-biotech-waters-with-a-fo-00f2039c62c0d646 2026-09-21T09:22:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/legend-biotech-corporation-legn-stock-analysis-unveiling-a-175-potential-upside-bcd9d089c6ca5a63 2026-09-21T09:22:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-inc-krys-stock-analysis-a-look-at-its-14-36-potential-upside-9a61874672731d38 2026-09-21T09:21:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/exelixis-inc-exel-stock-analysis-navigating-biotech-with-strong-revenue-growth-a-5788861c9117fa48 2026-09-21T09:21:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/nuvalent-inc-nuvl-stock-analysis-navigating-the-biotech-landscape-with-a-clinica-7e778788f7bae560 2026-09-21T09:20:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-extremely-bullish-as-telix-beams-into-novartis-territory-with-1-6b-itm-130dcd4d2d8d5288 2026-09-21T09:19:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/meningococcal-disease-enhanced-surveillance-form-969ec8a257418767 2026-09-21T09:15:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-pharmaceuticals-vrtx-stock-analysis-a-biotech-powerhouse-with-11-97-poten-386828f0479eef3f 2026-09-21T09:15:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/mycoplasma-genitalium-antimicrobial-resistance-surveillance-mars-8b728d0038ccd66f 2026-09-21T09:14:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-commercial-opportunities-9e4f936a0befa657 2026-09-21T09:09:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662 2026-09-21T09:06:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-suspends-pfizer-c-f-depot-licence-in-fake-drug-case-warns-consumers-ov-61ae4f712869af8f 2026-09-21T08:58:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/daewon-pharmaceutical-brings-shinbaro-in-house-to-expand-south-korea-osteoarthri-06deb3f19266a298 2026-09-21T08:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cue-chalks-up-phase-2-hives-win-for-xolair-challenger-dca24fea5b2e4874 2026-09-21T08:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-spurious-drugs-racket-fda-cancels-16-drug-licences-suspends-pfizer-c-f-583b24989cc671ce 2026-09-21T08:49:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/retension-and-lilly-backed-trex-bio-both-set-out-plans-to-join-biotech-ipo-stamp-d978dc40cc95aef6 2026-09-21T08:29:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/bofa-securities-lifts-sino-biopharmaceutical-target-to-hk-7-3-bullish-on-chinese-b25213c517e317db 2026-09-21T08:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nykredit-a-s-takes-position-in-teva-pharmaceutical-industries-ltd-teva-8ef68b53d2f7b566 2026-09-21T08:12:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/anthropic-bytedance-enter-ai-drug-discovery-the-next-coding-faces-critical-data-949e67c2cfec7bcb 2026-09-21T08:10:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/aspen-achieves-top-10-ranking-for-integrated-reporting-excellence-11891286e263540b 2026-09-21T08:04:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/buy-sun-pharmaceutical-industries-target-of-rs-2070-geojit-financial-services-05d4bece45133dba 2026-09-21T08:01:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-may-202-2cc50be828051e6c 2026-09-21T07:54:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-39-report-data-to-week-38-dat-1bbeb1fdd2fcb78d 2026-09-21T07:43:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/aston-university-joins-forces-with-biotech-firm-to-develop-realistic-human-skin-5439803eb98b58fb 2026-09-21T07:39:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korea-s-inventera-reports-phase-3-success-for-mri-contrast-agent-plans-reg-7e38950a6ba7475b 2026-09-21T07:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antengene-starts-phase-iii-clinch-3-trial-of-atg-022-in-advanced-gastric-cancer-02e84e96f3c002c3 2026-09-21T07:33:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-plans-more-support-for-pharma-innovation-f77ec0948695270f 2026-09-21T07:09:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/inventera-s-mri-contrast-agent-passes-phase-3-trial-in-korea-22fdf31a869b455e 2026-09-21T06:53:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/interview-mash-moves-beyond-clinical-graveyard-as-focus-shifts-to-targets-biomar-778863fe92e5aac3 2026-09-21T06:49:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/lavengratinib-shows-100-response-rate-in-lowest-dose-achondroplasia-cohort-c1eaa9b89bb2e951 2026-09-21T06:38:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-b2b1f4cf310740f2 2026-09-21T06:31:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/neurotech-international-initiates-phase-3-beyond-harmony-trial-with-first-patien-bc6f61556b31fc81 2026-09-21T06:20:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-aspen-betting-on-the-right-hiv-prevention-product-14903d010e56bd11 2026-09-21T06:19:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/copenhagen-biotech-takes-first-step-toward-european-approval-eyes-major-reformul-88ce2eac112529e9 2026-09-21T06:14:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-c-f-depot-licence-suspension-case-k-taka-health-dept-warns-consumers-over-62b3da0dab88be39 2026-09-21T06:13:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/beacon-lights-path-to-fda-approval-with-pivotal-trial-win-for-rare-vision-loss-g-de3d6ab41f73e76c 2026-09-21T05:57:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/cicc-cuts-alibaba-health-target-price-to-hk-4-5-bullish-on-pharmaceutical-busine-2ef4c2c59948d673 2026-09-21T05:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sunshine-guojian-pharmaceutical-co-ltd-xssc-688336-added-to-ftse-all-world-index-f7d596060f75cd57 2026-09-21T05:21:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-bio-joins-hands-with-bondwell-for-protein-production-82d9ae6b6395045f 2026-09-21T05:10:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/cybin-eyes-q4-phase-3-data-for-depression-drug-hlp003-fe46f092d7c7b986 2026-09-21T05:02:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/cybin-eyes-q4-phase-3-data-for-depression-drug-hlp003-0c74433ec5a2cf09 2026-09-21T05:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aluminum-pvc-blister-film-market-forecast-to-2035-pharmaceutical-demand-drives-5-953d6d97f21cf2cb 2026-09-21T05:01:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-week-ahead-xlv-beats-the-market-here-are-the-stocks-readouts-and-events-8162588003ba2afa 2026-09-21T04:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/north-china-pharmaceutical-company-ltd-xssc-600812-dropped-from-ftse-all-world-i-b96971880c9cd718 2026-09-21T04:35:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/heilongjiang-zbd-pharmaceutical-co-ltd-xssc-603567-dropped-from-ftse-all-world-i-4353837e375a403a 2026-09-21T04:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-phase-iii-diabetes-trial-start-require-action-from-uni-bio-science-shares-033cbff8c0320fac 2026-09-21T04:28:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/sansure-biotech-inc-xssc-688289-dropped-from-ftse-all-world-index-58517ea7bc89902e 2026-09-21T04:27:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/chinese-biopharma-stocks-jump-as-u-s-weighs-keeping-door-open-to-drug-deals-a80913ab3deb4527 2026-09-21T04:20:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-resources-boya-bio-pharmaceutical-group-co-ltd-xsec-300294-dropped-from-ft-b7061d9fea7cd209 2026-09-21T04:11:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-warns-texas-beverage-companies-about-acidified-food-unapproved-drug-claims-5909ec9e189f3706 2026-09-21T04:02:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/convenience-kit-correction-avid-medical-issues-correction-for-kits-containing-hu-1b4aecd26284ce1a 2026-09-21T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fake-pfizer-labels-expired-vials-seized-karnataka-fda-cancels-16-licences-suspen-94d0597343aefd1e 2026-09-21T03:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-bio-to-expand-into-protein-process-development-with-us-bondwell-999cb539da410bad 2026-09-21T03:26:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/celltrion-wins-ema-approval-to-modify-phase-3-trial-for-darzalex-biosimilar-ct-p-b83c8c64d39982d8 2026-09-21T03:25:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/shenqi-pharmaceutical-share-price-skyrockets-160-the-stock-is-truly-magical-2c0bba098ab6dc55 2026-09-21T03:14:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/nyrada-raises-fresh-capital-to-fund-xolatryp-phase-iia-and-pipeline-expansion-4c148b1b6b22f576 2026-09-21T03:10:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/kolon-tissuegene-ceo-noh-moon-jong-steps-down-after-tg-c-phase-3-failure-93ba35e01c4a0a62 2026-09-21T02:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fda-cancels-16-suspends-8-drug-licences-in-counterfeit-medicine-crackd-f0e2dfff72f4bb07 2026-09-21T02:27:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fda-uncovers-farmhouse-drug-scam-with-fake-pfizer-labels-fa113abe91479c41 2026-09-21T02:12:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/abl-bio-s-credibility-in-doubt-as-market-cap-drops-by-10-trillion-won-in-eight-m-6125fa47849c124e 2026-09-21T01:56:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/cha-biotech-s-us-unit-matica-expands-beyond-cgt-into-protein-cdmo-3e1fa8b19d2893e9 2026-09-21T01:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kolon-tissuegene-shifts-to-sole-leadership-as-no-resigns-after-tg-c-setback-chos-78b39badd6d85917 2026-09-21T01:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fda-cancels-16-drug-licences-after-rs-5-05-crore-spurious-medicine-rac-71f3f5a689bc8cb1 2026-09-21T01:25:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/hansoh-pharmaceutical-says-hs-10374-meets-co-primary-endpoints-in-phase-iii-plaq-c406088c5e696e9d 2026-09-21T01:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-anti-aging-to-biotech-taiwan-looks-to-take-its-exosomes-global-8b1cffaebe2d4f7a 2026-09-21T01:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antengene-announces-first-patient-dosed-in-pivotal-phase-iii-clinch-3-study-of-a-46d88b9387463d03 2026-09-21T00:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hansoh-pharmaceutical-pharma-announces-pivotal-phase-3-clinical-trial-of-hs-1037-5e494e720e07789d 2026-09-21T00:24:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/nephrotic-syndrome-clinical-trial-pipeline-gains-momentum-3-3dcb122cc4863365 2026-09-21T00:24:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-20d1e45ad8f41ec4 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-97a3580102cfaf35 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-f7733853b6214ae0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-tem-11a455d22d2f487e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-sta-3764daf81725a8e8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pri-46565154b7c80bf6 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-pro-a46738e923f10604 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-intermediaries-and-approaches-to-strengthen-public-health-data-exchange-4fc8495db52da975 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/request-for-information-on-electromagnetic-fields-emfs-radiofrequency-rf-radiati-adf4d970aa383e2a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/solicitation-of-nominations-for-membership-on-the-national-vaccine-advisory-comm-7829fc374a16ba21 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-medicare-rural-hospital-flexibility-program-evalu-34665635a9d20190 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-state-offices-of-rural-health-coordination-and-de-f3a019ef42d0893b 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/esther-villanueva-valdes-m-d-decision-and-order-6920fac42a4abfcb 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i-0219f45fb611f4fb 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/john-ramsay-walters-m-d-decision-and-order-508288de44a083a6 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-2cd2bb9dfe90d36a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-90b2d8c9d1af74ac 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-quality-improvement-technical-assistance-pr-9960416381329507 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cleveland-clinic-children-s-expands-newborn-screening-to-identify-virus-that-can-5be78e10f5542c12 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/best-shower-habits-for-healthy-skin-17d870af5aaadff9 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-regulatory-acceptability-of-hierarchical-composite-endpoints-in-inf-8fdddd6693552588 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preclinical-and-first-in-human-phase-i-trial-of-mt200605-a-novel-trkb-agonist-fo-1829f78db2d42e94 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetics-and-safety-of-a-modified-release-psilocybin-formulation-a-sad-p-b737575b41477429 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supporting-the-primary-outcomes-of-the-mirai-trial-for-the-adjunctive-digital-th-24ef5a380338f8fe 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cost-effectiveness-and-value-implications-of-veligrotug-versus-teprotumumab-for-7ece3f4eda8bff11 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-free-remission-in-early-peripheral-spondyloarthritis-including-psoriatic-ar-0aa0a17d1dd07f91 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-pharmacist-led-medication-review-on-drug-related-problems-among-outpat-d98465ff90ef3962 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-orthodontic-management-of-impacted-teeth-associated-with-retained-p-4cc1e189c772934d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/contemporary-classifications-of-alzheimer-s-disease-a-critical-review-of-clinica-881e2ebbb9a0f093 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-effects-of-myofascial-release-and-bowen-therapy-in-patients-with-tex-0ca1011620b24697 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/redefining-post-xenotransplantation-surveillance-leveraging-metagenomic-next-gen-b5529587c7664a12 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-answers-to-agents-what-must-change-before-generative-and-agentic-ai-become-29d767d349ffc4c0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-open-label-dose-escalation-trial-of-psilocybin-assisted-therapy-for-bipolar-i-d6af23c5c79be8b0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanotechnology-for-drug-delivery-systems-in-colorectal-cancer-recent-development-407dba257167da55 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/letter-to-the-editor-artificial-intelligence-in-hepatology-when-deep-learning-me-a568d88464097fac 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/polyethylene-glycol-based-bowel-preparation-and-gut-dysbiosis-clinical-implicati-0b34416aee8a965b 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/b3c94bebd28f7b8a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-the-dispensary-pharmacists-perspectives-on-the-responsible-implementation-cfbe71d78e165236 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/accelerated-wound-healing-with-a-bilayer-biodegradable-synthetic-matrix-in-post-ef236746b1d49e2c 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-longitudinal-analysis-of-the-clinical-practice-of-ketamine-assisted-psychother-6ab9b95624cbf138 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/precision-cut-tumor-slices-a-biomimetic-tool-for-accelerating-oncological-develo-7226c7cb1b69ee04 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-a-large-language-model-chatgpt-5-for-detecting-potential-drug-drug-in-816f2974050e0720 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/explainable-ai-based-prognostication-of-patients-with-resectable-colorectal-live-2fbabdacdf9df95d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-individualized-surgical-pathways-in-elderly-patients-with-s-8be373a0ada7c9ac 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cholesterol-in-hematological-malignancies-metabolism-mechanisms-and-clinical-imp-9a30fa29c2722f2e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/radiomics-and-deep-learning-for-immune-checkpoint-inhibitor-outcomes-imaging-der-c24c9e0431952223 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-hypertension-and-endocrine-pathways-molecular-and-clinical-perspective-f45527b617e638a0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-metabolic-indices-with-in-stent-restenosis-and-its-angiographic-s-e1466792d8c505f7 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-for-alcohol-opioid-and-cannabis-use-disorders-screening-af0d522dc83a2f40 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-endovascular-stenting-versus-bypass-surgery-for-aortoiliac-c8a13ad848e43792 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/experimental-data-analysis-and-improved-cytochrome-p450-site-of-metabolism-predi-c9f109a994421cca 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correlation-of-hematological-parameters-with-serum-ferritin-in-pregnant-women-fr-c9a73dba51df0812 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/semaglutide-effects-on-insulin-sensitivity-and-cell-function-in-patients-with-sc-75140098b7871905 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/myopia-control-effect-of-continuous-versus-sinusoidal-photobiomodulation-therapy-56eab16e14bc0b7e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-system-for-independent-evaluation-of-clinical-prediction-models-while-preservi-8fb78fb786fc2a3e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clostridium-ramosum-bacteremia-clinical-significance-and-outcomes-in-a-multicent-aed8148e87cde446 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-evaluation-of-surgical-management-of-humeral-fractures-in-dogs-630477cc2610da7a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-prediction-with-time-varying-predictors-in-pediatric-hospital-medicine-e1b6797d232c89eb 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/72120-role-of-cross-coupling-reactions-in-drug-discovery-and-development-c3d94fd4f2f85350 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-clinical-and-laboratory-findings-associated-with-mortality-during-continuo-9407e7b095fca8cf 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomized-trial-of-burr-hole-surgery-with-or-without-irrigation-for-chronic-sub-1a791efcaca9175c 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mir-107-serves-as-a-clinical-biomarker-for-acute-pancreatitis-and-promotes-infla-184ec7a1bcd62e51 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-age-and-outcomes-of-evidence-based-feeding-protocol-versus-u-55c081db85ef4e3d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-the-unified-treatment-for-emotion-regulation-an-95ba566aa1d0d048 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-environmental-burden-of-the-neuro-conda-trial-b843a9e61763332f 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-liberations-two-physiological-targets-implications-of-the-x-copd-trial-d4756dae96dd95bf 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-genetic-spectrum-of-dual-rare-genetic-diseases-revealed-by-whole-ex-c11cb01b29dfbeac 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparing-the-effectiveness-of-sexual-education-lactofem-probiotic-supplementati-6de2093c73f923ae 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-tricalcium-phosphate-grafting-on-implant-stability-and-peri-implant-ra-6c4647c34f739ce5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-clinical-outcomes-and-learning-curve-study-of-robot-assisted-precision-ost-e633bc562db9c390 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reproductive-health-factors-associated-with-clinical-breast-examination-uptake-a-1fb1bdc964c44801 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-it-possible-to-implement-the-dialog-routine-outcome-monitoring-system-in-a-ps-154907870f8fd3d8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/controlled-evaluation-of-architectural-classifier-and-training-refinements-in-mo-9b6b5ebafa237da4 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/allogenic-platelet-rich-plasma-in-joint-pathologies-a-scoping-review-of-basic-sc-ccb0239c5507a987 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-case-abstracts-presented-at-the-2026-vascular-scientific-sessions-of-th-17356abbdb3b6348 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-radiographic-outcomes-of-immediately-loaded-dental-implants-after-t-77d68a80ff7a1256 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/extended-follow-up-of-botensilimab-plus-balstilimab-in-an-expanded-cohort-of-mic-8871580c40903541 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/distinct-clinical-and-immunologic-patterns-of-interferon-release-assays-implicat-ca8762f7c7c8cfc5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bridging-the-gap-83b94f56544f36fa 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-case-of-acute-mania-and-rhabdomyolysis-associated-with-long-term-daily-psilocy-5e9ff14ba01f20d2 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/successful-linezolid-based-treatment-of-nocardia-otitidiscaviarum-pneumonia-in-a-75522611e0215260 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-clinical-significance-of-i-streptococcus-mitis-i-bacteremia-cb2e2d34699715bf 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-kdigo-2026-clinical-practice-guideline-for-anemia-in-chronic-kidne-a000d38d61280e8d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-of-tuberculosis-preventive-treatment-among-people-receiving-or-about-to-i-749f45684f85b3a3 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/plga-nanoparticles-co-loaded-with-resveratrol-and-doxycycline-for-dual-action-pe-939ca4ac398814e2 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-probiotic-supplementation-on-psychological-stress-in-healthy-adults-wi-a783c04adb8a175d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/history-of-instruments-and-technology-in-the-clinical-neurosciences-1-a-new-colu-20dd0b4b14d65df6 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-renal-replacement-therapy-and-short-term-mortality-in-higher-risk-kdigo-st-24cf7609b60ad216 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/features-and-a-specific-pattern-of-cerebral-perfusion-in-patients-with-lewy-body-355df3a541cce01e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplemental-material-for-an-intervention-based-on-acceptance-and-commitment-the-1d4752ceee3f7ec7 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanomaterial-driven-innovation-integrating-catalytic-quinoline-synthesis-and-ant-8cf496cf1a6deeee 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-frontal-qrs-t-angle-and-cardiovascular-disease-a-narrative-review-of-electro-cbbb96a76080672a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/omental-infarction-mimicking-acute-appendicitis-a-case-series-and-systematic-rev-abd897ddb9f816d8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bergen-barbers-a-student-run-haircut-and-grooming-service-to-enhance-empathy-cli-2d783afe88dd1ff0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-profiles-in-fda-approved-new-molecular-entities-2013-2024-a-latent-cl-14b45ca875a5e683 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/using-pre-study-patient-interviews-to-refine-electronic-patient-reported-outcome-180e87a5a4637f62 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/qualitatssicherung-in-der-notfallmedizin-klinische-routinedaten-zur-kontinuierli-9ef90c7e92ec7796 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/laparoscopic-visualisation-of-the-ureters-using-near-infrared-fluorescence-imagi-39abad0ed5393be8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vagus-nerve-stimulation-in-rheumatic-diseases-linking-autonomic-nervous-system-r-fc25d41224e56bfa 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/masking-effect-in-the-spanish-spontaneous-reporting-database-fedra-ed8e769df5841923 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-multicenter-randomized-double-blinded-placebo-controlled-phase-2-trial-to-eval-b630ccd85cfbb5fa 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shared-output-aptamer-gated-dna-nanodevices-program-nbasparda-trans-cleavage-for-4dd58d1aa5180db7 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-effectiveness-of-sialendoscopy-in-radioactive-iodine-induced-sialadenit-0b3e7d49e37b1880 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/osteomyelitis-epidemiology-classification-pathophysiology-clinical-features-diag-d34e3ed15fd784bd 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/atypical-varicella-like-presentation-of-an-imported-mpox-case-in-austria-confirm-17058169ca24c758 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/enabling-bioprocess-upscaling-prediction-through-hybrid-modelling-and-transfer-l-49d7f1ddf8c48684 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-free-remission-in-early-peripheral-spondyloarthritis-including-psoriatic-ar-6c81cca77d0e9b70 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-approaches-to-macrophage-activation-syndrome-in-real-life-and-prioriti-102fe79d4968ac65 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831876-a-study-of-ear-nerve-stimulation-to-treat-eye-inflammation-e4573db9274a7699 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831837-evaluation-and-implementation-of-digital-health-ecosystem-in-academi-fdcdcc46b03062f5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831304-randomized-prospective-trial-on-the-cost-effectiveness-of-photon-cou-447db65ba37a6fcc 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831265-a-prospective-randomized-controlled-trial-of-dynamic-fixation-for-co-55d0b71452ea5131 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831226-safety-and-immunogenicity-of-the-recombinant-malaria-vaccines-in-hea-2bcd3e04222cd35a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831161-safety-and-efficacy-of-autologous-natural-killer-cell-therapy-chank-7684ab7dca353214 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830836-physiotherapy-and-osteopathic-treatment-for-pain-in-the-cervical-and-20384e7f0eeba594 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830355-immunotherapy-plus-anlotinib-after-surgery-for-esophageal-squamous-c-5dd9b5e748bcb337 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830004-plasmatic-biomarkers-associated-with-short-term-luspatercept-treatme-9f16e1451340d3d9 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07829978-impact-of-diagnostic-and-therapeutic-upper-and-lower-gastrointestina-2f65ffa869894003 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07829809-serum-adropin-as-an-indicator-of-endothelial-dysfunction-and-disease-595c2cf7ea30a7af 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07819747-resources-and-education-for-addressing-chronic-health-reach-5c8914fdbf6ad407 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07796373-nemtabrutinib-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-38cf1b9c433f4464 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07793383-adaptive-decision-support-for-addiction-treatment-adapt-serial-rando-c8142426532c5676 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07744152-a-study-to-test-how-well-different-doses-of-bi-3822971-are-tolerated-89d0e68398e8cbf3 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07705880-a-novel-clinical-decision-support-tool-to-predict-submucosal-invasiv-73c69ebdf5d8163e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07693751-a-study-to-assess-safety-and-efficacy-of-sot109-in-patients-with-adv-14346cd0d70e71ff 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07616206-cadisegliatin-as-adjunctive-therapy-to-insulin-in-participants-with-5af473b6b56cac59 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07577661-combination-upper-airway-electrical-and-pharmacological-stimulation-898bbd982429e10a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07572240-a-clinical-trial-to-assess-the-effect-of-ap-brain-collagen-peptides-c72f6d5ff4530877 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07495943-effects-of-2-aticyto-complex-and-d-ribose-on-pain-and-clinical-cours-101475d12f61e662 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07266831-a-clinical-study-of-islatravir-and-ulonivirine-for-people-with-hiv-1-eee6bd7200b16053 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07262346-the-phase-id-clinical-trial-of-hydronidone-capsules-b492d9ed0ab0ced8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07248839-a-study-to-assess-the-drug-levels-and-safety-of-bms-986435-in-partic-6bcf7865fc797437 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07237217-guided-group-telehealth-to-deliver-evidence-based-therapeutic-care-t-429f74fb322a7209 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07232030-barostim-enabled-neurohormonal-intervention-for-improving-treatment-b8fbe5404be54fc1 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07211633-a-study-to-evaluate-the-pharmacokinetics-pharmacodynamics-safety-rad-9469e73414b30703 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07194044-metastatic-ewing-s-trial-testing-schedule-enhancement-to-improve-out-15ff028aa39b88b0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07161037-phase-2a-study-of-vx-407-in-participants-with-adpkd-who-have-a-subse-5b834aa1cbecaacd 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07111065-fast-for-dm-fatty-acid-supplementation-trial-fast-for-dermatomyositi-ed2b3f59cab40468 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06991738-177lu-dota-eb-tate-in-adult-patients-with-metastatic-radioactive-iod-8bb88397e09523fd 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06980077-ivonescimab-for-the-treatment-of-thymic-cancer-e1c7cd84dfd11be5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06948110-deciphering-the-genetic-architecture-of-autoimmune-diseases-353665cab37b522a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06904066-autologous-t-cells-transduced-with-retroviral-vectors-expressing-tcr-8a1bed717e911091 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06876142-combination-therapy-mirdametinib-and-sirolimus-for-ras-mutated-relap-84e0260330113171 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06843213-teaching-health-resilience-in-a-hospital-setting-a-peer-led-interven-728fcecdf8ae1e52 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06840262-target-muscle-re-innervation-and-regenerative-peripheral-nerve-inter-108eb92d9877d646 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06732401-testing-the-addition-of-azd6738-ceralasertib-to-immunotherapy-to-inc-c8470b82beaaa53e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06549595-a-study-of-surovatamig-azd0486-plus-rituximab-in-previously-untreate-07a6329d0563476d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06473532-text4hf-a-randomized-controlled-trial-of-a-tailored-text-messaging-i-ff5a3fb7b713be45 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06375915-precision-medicine-in-patients-with-unresectable-cholangiocarcinoma-1a7cbd79e9ebb164 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06368388-establishing-personalized-phage-therapy-and-its-comparative-cost-in-0a7ef44acf69cabe 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06337318-comparing-rituximab-and-mosunetuzumab-drug-treatments-for-people-wit-f9c0f74dff068b0e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06326047-a-research-study-comparing-how-well-different-doses-of-the-medicine-f6ec57cf0b2fe58d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06210373-assessment-of-efficacy-and-safety-of-the-use-of-two-eye-gel-products-0073804eb26c0a5c 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06149793-sglt2-inhibitor-therapy-in-cystic-fibrosis-related-diabetes-7fdca58a4e7cc302 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06120244-establishment-of-biobank-of-nasal-epithelium-samples-from-healthy-vo-147d3c56bb9915e2 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06038032-improving-health-behaviours-for-life-after-endometrial-cancer-trial-4118e5d6f2fdb4fe 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06005740-a-phase-1-first-in-human-study-of-torl-4-500-in-patients-with-advanc-c709207ba78bf3a0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05842330-benefits-of-adhd-treatment-in-detained-people-06046ff851a60e9f 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05383274-optilume-post-approval-clinical-evaluation-of-andrology-parameters-bc64816ab9b77eb5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05041309-long-term-follow-up-study-after-gene-modified-cell-treatment-in-kite-de88c2de50133c8a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04984005-the-interaction-and-regulation-mechanism-of-different-exercise-patte-093e891995b9f987 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04512209-characterization-of-biophysical-stromal-properties-in-human-cancer-t-4b671ba1b3860be3 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04359732-assessment-of-response-to-ncrt-for-gej-cancer-using-a-fully-integrat-8c8a048767bc00f6 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04018092-the-revitalize-study-in-older-adults-at-risk-for-alzheimer-s-disease-dbe5d764e71a0caa 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03226704-leukapheresis-for-car-or-adoptive-cell-therapy-manufacturing-8859eb3be74c76ca 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03223103-safety-and-immunogenicity-of-personalized-genomic-vaccine-and-tumor-f248e56d06f14a0a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02003222-combination-chemotherapy-with-or-without-blinatumomab-in-treating-pa-489f33c4c086296d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01496625-national-eye-institute-biorepository-for-retinal-diseases-99078260bf2b6307 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-halts-trading-ahead-of-phase-3-trial-update-aa25a9abde83efd3 2026-09-20T23:48:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/click-estock-aribio-holdings-set-to-announce-ar1001-phase-3-results-rapid-commer-cc4b1439181b24d5 2026-09-20T23:37:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/expert-team-to-drive-improvements-in-cancer-care-417d32b858766792 2026-09-20T23:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/market-movers-rx-west-pharmaceutical-services-leads-gainers-d11ab73a9d464311 2026-09-20T22:53:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998 2026-09-20T22:25:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32 2026-09-20T22:20:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/battles-in-u-s-war-on-cancer-being-waged-at-white-plains-hospital-d5ac453bc8b5b463 2026-09-20T21:37:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-escalates-warnings-on-compounded-glp-1-drugs-but-its-own-data-reveal-importa-784876c401fb6a60 2026-09-20T20:22:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-bet-on-biology-why-one-modality-is-never-enough-in-lung-cancer-22ddcff0c7b1d6de 2026-09-20T19:01:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-the-trial-fails-was-it-the-drug-or-the-design-7d9fc4711d67aecd 2026-09-20T19:01:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/liminal-biosciences-stock-remains-without-fresh-data-in-latest-search-window-e69750d05b62c05d 2026-09-20T18:36:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/igm-biosciences-stock-trades-quietly-amid-lack-of-fresh-data-7fcb87bd5c7cfbbd 2026-09-20T17:53:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/spurious-drugs-karnataka-fda-cancels-16-drug-licences-of-retailers-wholesalers-483f672ee324efee 2026-09-20T17:46:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-cancels-16-drug-licences-of-retailers-wholesalers-over-spurious-medici-2c63099044d2094e 2026-09-20T16:43:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-real-start-of-every-biotech-story-is-not-a-lab-but-the-funding-decision-c8c47d90798c3214 2026-09-20T16:42:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/counterfeit-drug-racket-karnataka-fda-cancels-licences-of-16-firms-suspends-eigh-75a62da78792156d 2026-09-20T16:27:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/k-taka-fda-cancels-16-drug-licences-of-retailers-wholesalers-c3da9512d4ad2b56 2026-09-20T16:19:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/spurious-drug-racket-busted-at-bidadi-farmhouse-rs-5-crore-stock-seized-37c1c944ca0872f9 2026-09-20T16:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-biotech-start-ups-need-patient-capital-to-drive-novel-drug-innovation-in-7b639daf4e308b1a 2026-09-20T16:03:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-reviewing-contraceptives-tied-to-meningioma-risk-e58870d2131fdd90 2026-09-20T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bidadi-fake-drug-racket-fallout-widens-karnataka-fda-cancels-16-licences-suspend-f5da6067ed6d5f34 2026-09-20T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cheap-drugs-fake-labels-non-functional-qr-codes-karnataka-fda-cancels-16-licence-30805af09704bb40 2026-09-20T15:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-busts-fake-drug-racket-suspends-license-of-pfizer-depot-7-other-firms-5a01456374a081c9 2026-09-20T15:39:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/novocure-nvcr-breaks-out-on-q2-2026-earnings-optune-pax-driving-recovery-d29aa8bbd69d100a 2026-09-20T15:34:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cancels-16-suspends-eight-drug-licences-in-karnataka-india-news-ba30705170e35c28 2026-09-20T15:25:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/sartorius-stedim-stock-holds-steady-as-investors-digest-recent-results-357e977aebe6ec21 2026-09-20T15:08:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/study-finds-no-neurodevelopmental-risk-in-prenatal-covid-19-except-speech-60978aa7141468f4 2026-09-20T15:06:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/fake-drug-racket-case-why-did-karnataka-fda-take-action-against-pfizer-and-other-c891e75d1209a28e 2026-09-20T14:47:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-3e00c4b5d346cd8c 2026-09-20T14:41:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-16-licences-cancelled-over-suspected-fake-drug-supply-0e40f8f1294379fe 2026-09-20T14:36:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-holds-near-fair-value-as-valuation-debate-int-4a13daa556aa57de 2026-09-20T14:28:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-is-drawing-attention-to-west-pharmaceutical-services-wst-92b5c124882ba4d9 2026-09-20T14:07:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/accelerating-digital-transformation-in-the-pharmaceutical-sector-61a20ba6a4cf5dbb 2026-09-20T14:06:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-society-calls-for-stronger-drug-regulation-f2db6216a77cc7af 2026-09-20T14:04:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-biotech-firm-innata-bio-moves-headquarters-to-philadelphia-s-lilly-gateway-la-c364a610699ace50 2026-09-20T14:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fda-cancels-16-pharmacy-licences-over-spurious-drug-racket-f06b08fa08cf993b 2026-09-20T13:57:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/fake-drugs-karnataka-cancels-16-licenses-suspends-8-including-that-of-pfizer-dep-72248dc68285db68 2026-09-20T13:56:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investors-dumped-ionis-pharmaceuticals-stock-but-wall-street-hasn-t-budged-from-ff4660a6a8ea5bfa 2026-09-20T13:55:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/spurious-drug-racket-busted-at-farmhouse-in-karnataka-s-bidadi-24-pharma-licence-55071d8965d7b532 2026-09-20T13:51:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-ultragenyx-pharmaceutical-rare-cheap-on-fayuvi-fda-approval-ba65c38fdef312f2 2026-09-20T13:44:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/gh-research-gets-fda-clearance-to-start-phase-3-trial-for-new-depression-treatme-1999373cc534630c 2026-09-20T13:34:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-warned-covid-vaccine-safety-tool-was-broken-then-silenced-doctor-who-told-th-f38dbda48e4ec923 2026-09-20T13:20:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/gh-research-buy-gh001-trd-advancement-presses-on-and-expansion-opportunities-325030f39a18e63e 2026-09-20T13:19:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fake-drug-racket-16-pharmacy-licences-cancelled-action-against-pfizer-08c4014b4de08ea9 2026-09-20T13:03:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-hpp-drug-candidate-wins-fda-priority-review-79549cc13ba282da 2026-09-20T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-raises-more-than-1-1-billion-for-public-biotech-fund-bring-8a89e2c526ed56c6 2026-09-20T12:50:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacists-protest-expansion-of-non-face-to-face-care-and-medication-delivery-2d8c26b6369332e5 2026-09-20T11:41:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/bytedance-s-favored-child-unveils-the-capital-game-of-the-ai-pharmaceutical-indu-604a2f26528da009 2026-09-20T11:13:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-price-today-teva-pharmaceutical-industries-limited-stock-price-quote-chart-8ccacc4f83865af8 2026-09-20T11:07:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/hospital-pharmacies-drug-distributors-come-under-fda-scanner-8b044166b5548d2a 2026-09-20T10:32:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/2-wall-street-analysts-think-argenx-can-soar-more-than-40-here-s-why-they-re-rig-f513a4249132800f 2026-09-20T10:31:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/cue-biopharma-announces-positive-topline-results-from-cue-221-phase-2-study-in-c-8b819eb2bbb81bc1 2026-09-20T10:17:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/multilayer-composite-filter-cartridges-market-forecast-to-2035-driven-by-tighten-48c160638f5d9a44 2026-09-20T10:16:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/2-wall-street-analysts-think-argenx-can-soar-more-than-40-here-s-why-they-re-rig-9739b0ac2a71928b 2026-09-20T10:12:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/nashik-fda-seizes-food-stock-worth-48-81-lakh-during-festive-inspection-drive-732b4a4f83191eb5 2026-09-20T10:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cue-biopharma-reports-positive-phase-2-topline-results-for-cue-221-in-chronic-sp-01dd38d09c11110d 2026-09-20T10:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-stock-falls-as-clinical-setbacks-weigh-despite-cosentyx-eu-boost-ae4da72e806448ab 2026-09-20T09:27:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-nih-funding-crisis-that-could-reshape-biotech-for-years-to-come-b62b5f7bdd7a60de 2026-09-20T09:18:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-price-today-teva-pharmaceutical-industries-limited-stock-price-quote-chart-8ba310a09d4d3d79 2026-09-20T09:04:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6f 2026-09-20T08:59:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558 2026-09-20T08:53:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82c 2026-09-20T08:43:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/kathmandu-pharmaceutical-association-urges-legal-operation-of-pharmacies-3039b3bd045c8d73 2026-09-20T08:30:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-holds-a-moderate-buy-rating-f8faf2c1ee001e7e 2026-09-20T08:25:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/ingrid-zhang-excited-to-advance-legend-biotech-s-mission-and-transform-patient-o-c737cea7423c9618 2026-09-20T07:17:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/liver-injury-fda-warning-for-tavneos-patients-0a86acc18b6c86db 2026-09-20T06:47:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/we-need-to-balance-business-livelihoods-with-public-health-says-maharashtra-fda-cadd731e9a9abe0c 2026-09-20T05:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-pharmaceutical-tightens-china-unit-controls-after-receivables-risk-chosunb-99641c81ca75d958 2026-09-20T05:09:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumbai-cafe-visited-by-tom-holland-matt-damon-and-christopher-nolan-loses-licenc-66f4b9289871ea70 2026-09-20T04:45:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/rest-of-asia-pacific-process-analytical-technology-market-size-share-trends-grow-63a8de689d51c9aa 2026-09-20T04:22:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-truth-about-msg-1968-prank-letter-that-started-a-50-decade-myth-bdfbbbdceed9e3fb 2026-09-20T04:00:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-could-be-10-undervalued-on-glp-1-and-annex-1-de-450d25329be4d6e4 2026-09-20T03:54:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/kaist-develops-new-catalyst-technology-for-complex-pharmaceutical-synthesis-c3c0f350dea7f0f8 2026-09-20T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/croda-opens-global-biotech-r-d-centre-in-uk-185f240d9d5e36c2 2026-09-20T02:49:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/anthropic-builds-biology-lab-in-san-francisco-to-accelerate-drug-discovery-d780d94f7dedf9a9 2026-09-20T02:39:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/csafe-launches-silverskin-re-pmc-reusable-thermal-cover-for-pharmaceutical-air-f-9773a41f94db98a1 2026-09-20T02:35:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-declares-bid-for-global-drug-innovation-dominance-by-2030-7e1f328ec4984e65 2026-09-20T01:59:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/anthropic-opens-san-francisco-biology-lab-to-speed-preclinical-drug-r-d-chosunbi-749840280cf686cd 2026-09-20T01:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-cosmetics-with-high-function-and-high-content-ingredients-are-eme-d5bdb04201e31beb 2026-09-20T01:33:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/dr-congo-expands-ebola-vaccination-to-ituri-over-3-700-vaccinated-047055f5d7c00cad 2026-09-20T01:23:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/raid-on-abl-bio-shakes-confidence-in-k-biotech-sector-61fe57bbfb60db99 2026-09-20T00:39:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/stanford-s-virtual-biotech-turns-37-000-ai-agents-into-a-drug-discovery-factory-6211ed771f1838af 2026-09-20T00:20:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800 2026-09-20T00:06:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-evidence-hierarchies-an-intervention-aware-contextual-systems-framework-f-03b7fbeb7b66b404 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emerging-therapeutic-strategies-and-clinical-development-of-investigational-agen-5ad2563cda00a9aa 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-two-commercially-available-topical-gels-as-adjuncts-to-3e242aaa23a99262 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-and-inflammatory-biomarker-changes-after-intravenous-ketamine-9ffa70defb76dc3a 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-dermoscopic-and-histopathological-correlation-of-pigmented-skin-lesions-c6145a7d2a81fae7 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dynamic-interactions-between-tumor-associated-macrophages-and-breast-cancer-cell-b1c9964f3d00bdfc 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-drug-repurposing-potential-of-natural-products-molecular-targets-pharmac-3b6b1335f539e8b8 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/concurrent-use-of-herbal-medicines-and-prescription-drugs-and-potential-herb-dru-1b19d6e302bf62e7 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vital-pulp-therapy-contemporary-concepts-materials-and-clinical-outcomes-a-narra-39cd8515ac92c91e 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-traditional-endodontics-with-vital-pulp-therapy-a-contemporary-revie-0c1584bd96cb3876 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-pelvic-inflammatory-disease-pid-among-women-of-reproductive-and-perimeno-08a675571af30cfd 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/7-clinical-significance-and-imaging-techniques-of-weight-bearing-radiography-6b4f8857f8b4dbed 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-outcomes-of-patients-without-an-attendant-admitted-to-the-e-0c9a353a1ee8ffeb 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-outcome-of-louse-borne-relapsing-fever-among-patients-seen-2033a2162f917eb0 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/microwave-breast-imaging-a-review-of-clinical-potential-and-technological-advanc-5e9290688094301c 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-in-ophthalmology-from-diagnostic-accuracy-to-clinical-ap-1fd69aa3ee10e722 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/culture-conversion-and-drug-susceptibility-in-drug-resistant-pulmonary-tuberculo-760f453f0ef28ed1 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bone-specific-alkaline-phosphatase-as-a-marker-of-bone-formation-clinical-and-im-bb8c60f2f1a2bbf9 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/precision-medicine-in-diffuse-large-b-cell-lymphoma-integrating-molecular-biomar-e12408836930ea28 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evolving-molecular-epidemiology-and-antimicrobial-resistance-of-streptococcus-ag-f4af1e23a3a99148 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/molecular-mechanisms-epidemiology-and-clinical-implications-of-macrolide-resista-4b7c7553c8d37028 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/macrolide-resistant-mycoplasma-pneumoniae-laboratory-diagnosis-and-epidemiology-00c61260210edeaf 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/generative-ai-for-drug-discovery-gpt-2-and-lstm-based-models-for-designing-egfr-be331195ce66e861 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-critical-examination-of-the-principle-of-proportionality-in-indonesian-food-an-fcf1c94dc7be344c 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mesenchymal-stem-cells-as-a-therapeutic-treatment-for-osteogenesis-imperfecta-cu-e072c0f354a4ea8d 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-serum-anion-gap-and-angiographic-severity-of-coronary-artery-dise-7fec8997e4390d0d 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessing-the-severity-and-persistence-of-depressive-symptoms-in-patients-with-a-cafa3d208182786f 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-imaging-to-intervention-insights-from-nuclear-imagingin-revascularization-s-42a53e36ac487ef0 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pop-culture-psychopathy-how-media-exposure-affects-laypersons-recognition-of-cli-105ad74b143a54ea 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-generalizability-gap-in-aortic-stenosis-analysis-of-87-clinical-trials-vs-re-462f7fdf6223115c 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/premature-children-s-developmental-outcomes-following-a-cognitive-behavioral-the-5c454b005b379d8b 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-smart-water-flosser-on-oral-health-in-children-aged-3-6-years-a-ra-b063cc8927bd0054 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-hd-tdcs-with-task-oriented-upper-limb-training-after-stroke-a-rand-6f59653cb40a0544 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pleomorphic-adenoma-of-the-upper-lip-a-case-report-with-histopathological-and-cl-792dd50f5fa1863e 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/charlson-comorbidity-index-in-predicting-postoperative-complications-and-long-te-4da7c00fc6503664 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-value-of-tissue-mrna-and-microrna-expression-profiles-for-differentia-2bddcda45b23b852 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-functional-and-clinical-outcomes-following-intramedullary-nailing-6fb028cd952f9fd5 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-retrospective-clinical-analysis-of-amir-kabir-s-migraine-a-microhistorical-app-dad5b514d33c37f9 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/online-education-program-communication-effectiveness-and-communication-self-effi-c61939f87ae542ac 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tarlatamab-treatment-for-metastatic-small-cell-neuroendocrine-carcinoma-of-the-b-665d1ff5d5c710e5 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/unexpected-lack-of-efficacy-of-liposomal-encapsulated-daunorubicin-cytarabine-in-f3201b034cab8a05 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-pcwg4-a-missed-opportunity-to-make-bone-protective-agents-mandatory-for-7a9a4131b9d688d0 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-beyond-response-rates-interpreting-long-term-benefit-in-checkmate-743-a-680b2d81daece5b2 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-statistical-significance-methodologic-fragility-and-censoring-bias-in-the-5888645062177c61 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rituximab-maintenance-added-to-ibrutinib-containing-therapy-in-younger-untreated-f591e24ba0a91e9b 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarker-stratified-phase-ii-trial-of-trastuzumab-rezetecan-in-advanced-salivar-e9a9c59fc3d6e970 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pcwg4-a-missed-opportunity-to-make-bone-protective-agents-mandatory-for-patients-ad9901af9cd08618 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/balancing-risk-benefit-and-reality-navigating-early-phase-studies-in-pediatric-d-b48bafd2e92e4718 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/darolutamide-alone-and-in-combination-with-goserelin-in-androgen-receptor-positi-392f7023f6ac4646 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mosunetuzumab-with-response-adapted-polatuzumab-vedotin-and-obinutuzumab-in-untr-e44840b20d6dfe8c 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/laser-interstitial-thermal-therapy-for-brain-tumors-a-prospective-multicenter-an-09e60a65ac19d6f3 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/long-term-follow-up-of-jcog1008-a-randomized-phase-ii-iii-trial-of-chemoradiothe-b4cc18dcf9a39115 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessing-improved-surveillance-of-leprosy-drug-resistance-in-madagascar-a-pilot-8c4a97f423db1efe 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-and-factors-associated-with-lower-pole-ptosis-recurrence-after-83dea2b3c8709bc6 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scalable-clinical-proteomics-from-dna-rna-extraction-flowthroughs-enables-integr-67f4d99a37666c5e 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-drug-interaction-between-alpinetin-and-glimepiride-and-its-potential-mechan-3fe3d3d640e3aac3 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/individualized-breast-cancer-survival-prediction-in-clinical-practice-a-seer-der-3515bc4647f92f29 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vestibular-rehabilitation-therapy-in-turkey-insights-into-physical-therapists-cl-e15ab512d701d115 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/delayed-antiretroviral-refills-as-an-early-clinical-alert-a-pharmacist-led-strat-5ed4eb24ac199b96 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-external-validation-of-prediction-models-for-a-trial-informed-op-734bcdaeee93453a 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bedside-infrared-thermometry-compared-with-continuous-zero-heat-flux-thermometry-3288242dafa136ce 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-marine-drug-plitidepsin-alleviates-osteoporosis-in-estrogen-deficient-mice-b-515952451def30c3 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrated-sustainability-and-risk-assessment-of-spectrophotometric-methods-for-37c16b3a77f6077e 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multicenter-dataset-describing-emotional-intelligence-and-counseling-self-effica-6689624137da0a45 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-serum-cotinine-levels-and-prostate-related-clinical-endpoint-c4f852f4c83f757b 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/understanding-the-impact-of-multiple-long-term-conditions-mltc-on-the-completion-e5c5b1b4afada493 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interest-in-geriatric-medicine-training-among-health-and-social-care-professiona-9f3f04d231090ca3 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-who-isop-pharmacovigilance-curriculum-2026-update-caba9d183fe05317 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/upstream-regulatory-mechanisms-and-clinical-significance-of-iqgap2-deficiency-in-606950dc4cbfd91d 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/identification-of-sst-as-a-glioblastoma-diagnostic-biomarker-via-integrated-bulk-68922ea308c6ef9b 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/slfn5-correlates-with-tumor-immune-microenvironment-and-clinical-outcomes-of-imm-9ab3dc157165f755 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/confounding-by-indication-in-the-evaluation-of-neoadjuvant-chemotherapy-a-sequen-a053b317c6b33cac 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bridging-the-data-latency-gap-automated-extraction-of-genomic-biomarkers-from-un-5a6e7536de41241b 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomized-trial-comparing-esophageal-resection-versus-substitution-alone-for-co-2c1a150a1149681d 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-genetic-polymorphisms-with-response-to-preoperative-nsaids-in-end-27f802965350b2c4 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/metabolomics-of-immunosenescence-bridging-blood-biomarkers-and-metabolic-pathway-71710cedb23a4736 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/persistent-foot-and-ankle-pain-in-rheumatoid-arthritis-remission-what-is-the-tre-ec95eeebc6741fa8 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncogene-driven-genomic-profiles-are-linked-to-poor-overall-survival-in-muscle-i-ad57ae7a9b681197 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/visual-snow-syndrome-as-a-neuropsychiatric-network-disorder-clinical-features-me-8b7cb71781bfa6e8 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-clinical-and-follow-up-data-in-patients-with-mycosis-fungoides-a-1-78724b981987fd8f 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fear-of-isotretinoin-in-moderate-to-severe-acne-clinical-impact-and-a-new-assess-b676c6d7f12c9224 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/imaging-in-gynecological-disease-32-clinical-and-ultrasound-characteristics-of-e-d66a8d1c162ad3b3 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/statins-as-repurposed-anticancer-agents-regulated-cell-death-the-tumor-immune-mi-876ff52221583627 2026-09-20T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/muireann-counihan-the-school-of-pharmacy-and-pharmaceutical-sciences-c41c155632d597a0 2026-09-19T23:15:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/krx-healthcare-shifts-to-large-caps-as-korea-favors-new-tech-biomed-chosunbiz-b426b824b83acf3d 2026-09-19T23:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-voice-the-school-of-pharmacy-and-pharmaceutical-sciences-241a1a36f55a527c 2026-09-19T22:50:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/total-common-shares-outstanding-of-indrayani-biotech-ltd-right-2026-25-06-26-for-d681acd0241805f0 2026-09-19T21:04:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/return-on-assets-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ind-501f187a0924faec 2026-09-19T21:04:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/net-current-asset-value-per-share-of-indrayani-biotech-ltd-right-2026-25-06-26-f-e6b6622493611352 2026-09-19T21:03:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/total-debt-per-share-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-16236a055fbe9757 2026-09-19T21:02:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/quick-ratio-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-6581b40f0bba1e8d 2026-09-19T21:02:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/messenger-rna-based-flu-vaccine-makes-its-debut-in-u-s-pharmacies-who-can-get-it-efefc51acff05862 2026-09-19T21:01:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/inventory-turnover-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-i-5671ae1604807dc6 2026-09-19T20:59:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/enterprise-value-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ind-4dff78ae4aa050db 2026-09-19T20:59:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/capex-per-share-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indr-944f01d354552ab8 2026-09-19T20:56:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/debt-to-equity-ratio-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-310711ff40bee6dd 2026-09-19T20:56:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-cash-flow-ratio-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-9af57061cd64e28a 2026-09-19T20:55:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/book-value-per-share-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-fc227e4d6c502179 2026-09-19T20:55:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/debt-to-assets-ratio-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ad7a8697f95d971c 2026-09-19T20:55:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-indrayani-biotech-ltd-right-2026-25-06-26-fo-7d4300fa5e85e482 2026-09-19T20:55:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/operating-margin-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ind-a7fd04be177b342e 2026-09-19T20:54:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/net-margin-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-44ae08b901252b4e 2026-09-19T20:54:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-biotech-without-humans-stanford-deploys-37-000-agents-to-hunt-new-therapies-d11375b86fdfc5b8 2026-09-19T20:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-migraine-franchise-scored-a-big-win-is-this-dividend-king-a-no-brainer-b83b918d40843782 2026-09-19T20:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-migraine-franchise-scored-a-big-win-is-this-dividend-king-a-no-brainer-76f1564f042c6f89 2026-09-19T19:48:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/indrayani-biotech-ltd-right-2026-25-06-26-for-shares-revenue-breakdown-bse-indra-ba030f2dd73a0499 2026-09-19T18:45:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/operating-expenses-excl-cogs-of-indrayani-biotech-ltd-right-2026-25-06-26-for-sh-2736dd784b3621df 2026-09-19T18:22:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/aap-ki-nazro-se-kuch-bachta-nahi-mallika-sherawat-thanks-fda-chief-tukaram-mundh-74720aa7f91d7267 2026-09-19T17:56:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/book-value-per-share-of-teva-pharmaceutical-industries-limited-ls-906517-b020b70e7daa0d95 2026-09-19T17:02:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/secret-contracts-reveal-undisclosed-terms-in-trump-s-drug-pricing-deals-bcbb413fb30f9d63 2026-09-19T17:00:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/dftx-vs-cmps-which-stock-has-more-upside-from-trump-s-new-psychedelic-therapy-pu-ef64dcf5e3960581 2026-09-19T16:56:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/cost-of-goods-sold-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-i-b0630789d0593e12 2026-09-19T16:51:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-charity-launches-ebola-vaccination-study-in-drc-5ceb6dd202441036 2026-09-19T16:44:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/pretax-income-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-25138c424a649553 2026-09-19T16:30:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/total-revenue-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-e381ce93b7e938a6 2026-09-19T16:29:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/total-operating-expenses-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-91c124a406c23076 2026-09-19T16:29:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/cash-flow-from-operating-activities-of-indrayani-biotech-ltd-right-2026-25-06-26-231dd929df858043 2026-09-19T16:28:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-direct-to-patient-is-redefining-drug-pricing-f6ef53a75af94d90 2026-09-19T16:27:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/cash-flow-from-financing-activities-of-indrayani-biotech-ltd-right-2026-25-06-26-5f765c6bb4d289be 2026-09-19T16:26:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/cash-flow-from-investing-activities-of-indrayani-biotech-ltd-right-2026-25-06-26-f5e9efda9ca345a9 2026-09-19T16:25:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/average-basic-shares-outstanding-of-indrayani-biotech-ltd-right-2026-25-06-26-fo-ff947f5470cc2ca9 2026-09-19T16:24:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/free-cash-flow-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-a3b2458b02b59529 2026-09-19T16:19:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-consider-september-19th-5211e452c4824f48 2026-09-19T16:04:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-melanoma-vaccine-was-hailed-as-a-breakthrough-which-cancers-are-next-9724080badd419c9 2026-09-19T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/operating-income-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ind-22b6730b871044c2 2026-09-19T15:33:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/discontinued-operations-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-739c09f0cac42098 2026-09-19T15:32:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/net-income-before-discontinued-operations-of-indrayani-biotech-ltd-right-2026-25-29c58a19d8e3561c 2026-09-19T15:32:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/non-operating-income-total-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shar-f8f77254f0db8c18 2026-09-19T15:31:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebit-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-3d34754992cd42f7 2026-09-19T15:31:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-stock-holds-moderate-buy-rating-as-annex-1-work-shapes-outlo-3c0fd62fb4220ec9 2026-09-19T15:29:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/preferred-dividends-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-7b282f168c26acd9 2026-09-19T15:28:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/diluted-shares-outstanding-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shar-fe37fa0a86d75c4c 2026-09-19T15:28:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/indrayani-biotech-ltd-right-2026-25-06-26-for-shares-7015c7d5b069f15a 2026-09-19T15:25:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/dilution-adjustment-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-2a92242613664e93 2026-09-19T15:24:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/net-income-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-7bf5aee9b121472e 2026-09-19T15:23:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/taxes-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-105d223587366115 2026-09-19T15:23:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/equity-in-earnings-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-i-6152711dc8c0ba7a 2026-09-19T15:23:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebitda-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-a4a85e2a8c739394 2026-09-19T15:22:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-takeda-s-orzeyful-as-first-drug-to-treat-narcolepsy-type-1-cause-49d3fb93ffe19a13 2026-09-19T14:37:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncolytics-biotech-stock-lacks-a-fresh-catalyst-and-stays-near-0-77-4ef9f2145181d3bb 2026-09-19T14:17:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-is-drawing-fresh-attention-to-biomarin-pharmaceutical-bmrn-dd7670b3b7f47046 2026-09-19T14:12:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-investors-are-reacting-to-ultragenyx-pharmaceutical-rare-first-in-disease-ge-39556364aa63f8c2 2026-09-19T14:10:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/oveporexton-met-primary-key-secondary-end-points-in-phase-3-studies-f55b262789759abc 2026-09-19T14:10:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/doctors-without-borders-launches-ebola-vaccination-study-in-dr-congo-bfd423e85dc532e3 2026-09-19T14:02:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-transparency-bill-stripped-of-critical-provisions-ahead-of-senate-vote-b7b7e4539be30c15 2026-09-19T14:01:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumbai-s-olympia-coffee-house-where-christopher-nolan-and-matt-damon-had-chai-fa-45ca75e3790f9d9d 2026-09-19T13:44:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/egg-recall-linked-to-salmonella-upgraded-to-highest-risk-level-by-fda-151a459787e48b10 2026-09-19T13:40:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/collegium-pharmaceutical-stock-edges-lower-as-analysts-keep-moderate-buy-stance-474386a21dda61b3 2026-09-19T13:33:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/where-nolan-tom-holland-had-chai-mumbai-cafe-faces-fda-licence-suspension-653993cb5cb20817 2026-09-19T13:04:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/passaparola-21-09-120-anni-della-clinica-mangiagalli-celebriamo-la-culla-d-itali-b6f1cc699352db07 2026-09-19T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/opthea-limited-stock-steadies-as-phase-3-trial-progress-drives-investor-focus-7dd5c0af77aa118a 2026-09-19T12:29:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/more-than-3-million-bottles-of-eye-drops-sold-at-cvs-kroger-more-voluntarily-rec-841b0d51339f6bee 2026-09-19T12:26:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/mallika-sherawat-praises-maharashtra-fda-commissioner-tukaram-mundhe-amid-state-3d5cc3b648250527 2026-09-19T12:15:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/macrogenics-stock-edges-lower-as-biotech-analysts-highlight-risk-and-upside-e9cf4e74587d279d 2026-09-19T12:15:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-tiny-biotech-is-beating-mrna-iova-and-sls-here-s-how-a-billionaire-fueled-i-f9fadbaa2502bed3 2026-09-19T12:01:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/rassegnastampa-tumori-in-eta-pediatrica-favorire-le-prospettive-di-guarigione-ne-533dc6a088ec60ce 2026-09-19T11:58:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/latus-bio-adds-biotech-veterans-as-gene-therapies-enter-clinic-d758e89343372953 2026-09-19T11:37:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/chip-tech-to-biotech-ce2e02f56139299f 2026-09-19T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/basic-earnings-per-share-basic-eps-of-indrayani-biotech-ltd-right-2026-25-06-26-6078a04cee3109b7 2026-09-19T11:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2 2026-09-19T10:43:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-10-pharmaceutical-manufacturing-companies-in-africa-in-2026-b4a1093df370deb8 2026-09-19T10:42:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/emirates-biotech-uae-university-partner-on-food-waste-plant-for-biogas-compost-5fbfd1099eb088db 2026-09-19T10:33:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/cassava-sciences-stock-holds-near-recent-lows-as-biotech-losses-and-mixed-sentim-d4ec6f7ef586a00b 2026-09-19T10:10:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-examines-use-of-testosterone-prescriptions-for-menopause-ad0f106a02d24ff0 2026-09-19T10:05:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/tirupati-group-appoints-uday-k-potdar-as-chief-financial-officer-339f006e241d5b8d 2026-09-19T10:01:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-approves-marine-biotech-policy-targets-6-8-bn-blue-bioeconomy-by-2031-2fb7e60f353058d0 2026-09-19T10:00:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/another-novartis-failure-novo-drops-the-nordisk-and-more-12d3d548f946c7a8 2026-09-19T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccinex-stock-holds-at-1-00-dollars-as-investors-await-fresh-trial-and-earnings-e39c8770527cfb72 2026-09-19T09:32:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/ordinary-people-pay-price-iran-medicine-shortages-deepen-as-war-continues-25bdcfd142278ade 2026-09-19T09:30:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-joke-to-amitabh-rekha-reference-samay-raina-s-latest-latent-episo-32630065385d1595 2026-09-19T09:27:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-wins-fda-approval-for-mimrylo-triggers-275m-payout-to-protagonist-819356fbe3d593e7 2026-09-19T09:16:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekend-longforms-organ-donation-false-pregnancy-tests-cancer-drug-ai-for-diagno-94dc4d3b8d04d5d9 2026-09-19T09:09:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicine-shortages-deepen-in-iran-amid-war-shipping-restrictions-1722387ef29ee867 2026-09-19T08:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ganpati-meets-food-safety-navi-mumbai-pandal-honours-tukaram-mundhes-fda-work-wi-8edca60af6c53510 2026-09-19T07:37:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/equity-in-earnings-of-zhuhai-trinomab-pharmaceutical-co-ltd-class-a-sse-688806-e04ee5f175d57b5a 2026-09-19T07:27:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-book-forward-of-henan-taloph-pharmaceutical-stock-co-ltd-class-a-sse-60-2bc42da5d2afe758 2026-09-19T07:27:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-s-tev-749-olanzapine-lai-shows-80-stabilization-rate-in-schizophrenia-trial-90a9d7a77742a0d4 2026-09-19T06:42:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-imlunestrant-plus-abemaciclib-for-esr1-mutated-breast-cancer-3c625593f647ec48 2026-09-19T06:37:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/alumna-employs-biotech-to-create-sustainable-livestock-production-f241526028de166d 2026-09-19T06:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/remember-when-christopher-nolan-and-tom-holland-visited-now-this-legendary-colab-a24659359e79565b 2026-09-19T05:28:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/neuphoria-to-be-acquired-by-scancell-in-all-stock-merger-b15a4e3511e1bdbf 2026-09-19T05:23:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/iraq-customs-clarifies-duties-on-pharmaceuticals-vitamins-and-supplements-8cc25463c2e436b0 2026-09-19T05:13:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-18-2026-177f47cf9e1b228b 2026-09-19T05:07:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/welcome-to-the-mammosphere-f5899a492f6d03cd 2026-09-19T02:45:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-annex-1-upgrades-at-west-pharmaceutical-services-wst-have-changed-its-invest-c6d42c01254a7c15 2026-09-19T02:42:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumbai-latest-news-today-on-september-19th-2026-train-blocks-fda-action-universi-425568d9eca4bec5 2026-09-19T02:41:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-halts-one-lung-cancer-trial-after-mixed-phase-3-results-aba6e0c9f3b21761 2026-09-19T02:26:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-hearing-psychedelics-launch-needs-balanced-regulation-without-limiting-acces-81cc63fd87c8c2d5 2026-09-19T02:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-amgen-tezspire-meets-phase-iii-eoe-trial-endpoints-f0706148fc31c54c 2026-09-19T01:34:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/homilia-te-deum-una-casa-edificada-sobre-roca-470e28c9f1d5d8c9 2026-09-19T00:08:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/transarterial-infusion-chemotherapy-and-embolization-as-a-novel-neoadjuvant-ther-7aac60eaf852135b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neo-bcv-induces-macrophage-associated-immunometabolic-remodeling-and-anti-tumor-0c165255b6a8071f 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-center-for-mucosal-immunobiology-and-rheumatic-disease-pathogenesis-ad-ce3f4f297554093f 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-assessment-of-sound-waves-from-liver-vessels-via-artificial-intelligen-726e97171cd2884b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-center-for-mucosal-immunobiology-and-rheumatic-disease-pathogenesis-su-a66a38a35676dd79 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-the-impact-of-environmental-factors-on-lewy-body-dementia-combining-cl-bcec376208ebe47b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mechanisms-of-action-of-peripheral-nerve-stimulation-for-the-treatment-dcccb23cc737b2e0 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-behavioral-science-strategies-to-increase-hypertension-diagnosis-and-t-e095a6e97192775b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-determining-the-shared-neuronal-network-mechanisms-of-focal-epileptic-b6d3e635ed9140d5 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-archery-artificial-intelligence-based-radiotherapy-treatment-planning-b823331c39831fc2 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-innovative-rapid-enabling-affordable-point-of-care-hpv-self-testing-st-008d3825e5485c4a 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-elucidating-how-transcription-factors-mafa-and-mafb-and-mitochondrial-46ddd28a0a3e6fd6 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-nutrition-late-fetal-and-neonatal-mortality-in-the-african-context-fabc6b96044ad32b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-resource-core-221219f1b12f5ae7 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-methodology-core-c191a15254234951 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-admin-core-875561f00d160f13 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-american-joint-replacement-research-collaborative-ajrr-c-6d0ec3548e3e09ad 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-helicobacter-infection-and-liver-cancer-risk-among-african-americans-a-c51972987d6896c9 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-and-safety-of-suhuang-zhike-capsule-for-post-infectious-cough-a-multice-36ac1b41d34dc91e 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-impact-of-antihypertensive-de-escalation-a-secondary-analysis-of-systolic-bl-8788c16a1547f799 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-abcb1-genetic-polymorphisms-with-treatment-outcomes-in-patie-874fb86fbbc60b16 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safe-medicine-storage-and-disposal-among-pharmacy-and-engineering-students-a-kap-e3e2d4de32f25ed1 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mpox-outbreak-in-cote-d-ivoire-during-2024-epidemiological-clinical-virological-2027dc5ac6527c47 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regenerative-medicine-in-the-management-of-musculoskeletal-pain-mechanisms-clini-d650a4d034f3b544 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-of-minimally-invasive-technologies-in-the-treatment-of-obstruc-b2e082ddcb04ca29 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-role-of-physicians-in-child-and-adolescent-psychiatry-exploring-the-therapeu-95303ae91b93ede6 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/examination-of-international-strategies-and-collaborative-efforts-in-responding-dcbf1a1c7f477fb6 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-gs-441524-in-the-management-of-feline-infectious-peritonitis-a-clini-2b94abafbc0802b3 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-nfl-and-gfap-levels-and-their-association-with-anxiety-depression-in-alzhe-38114244d078d939 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/takotsubo-syndrome-a-review-of-psychobiological-mechanisms-and-clinical-practice-796f14de12226bad 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-correlation-to-intervention-translating-the-psychological-network-of-adoles-b02a37b1b055f61e 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-thiet-lap-ca-hai-tham-so-cua-bieu-o-kiem-soat-noi-kiem-hanh-lang-can-tre-a089bde4f7254a16 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-khao-sat-chi-so-triglyceride-glucose-lt-b-gt-lt-b-gt-tyg-lt-b-gt-lt-b-gt-9aa3330e763554d0 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-the-site-of-pain-fascial-continuity-and-integrated-clinical-reasoning-in-0df9516427501ea6 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proenkephalin-penkid-in-renal-dysfunction-an-integrative-review-of-laboratory-an-93660ff9cfd11b01 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regenerative-medicine-at-the-crossroads-of-innovation-evidence-and-clinical-resp-05677a7f689b1c65 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-laboratory-profile-of-i-mycoplasma-pneumoniae-i-pneumonia-among-chi-552f7c94137766f9 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inguinal-hernia-as-a-systemic-enzyme-dysfunction-disorder-a-prospective-comparat-e64f9953548400b0 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-psychological-impact-of-covid-19-and-mental-relaxation-practices-by-amateur-073b7c79da9ccae2 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ethnomedicinal-utilization-of-rauwolfia-serpentina-l-benth-ex-kurz-7d5ee8c80c1d7646 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/computational-exploration-revealed-nicotiflorin-as-a-potent-dpp4-inhibitor-for-d-5a77b6dc254be1b5 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-validation-of-a-reverse-phase-high-performance-liquid-chromatogr-ec3e92366fb1a9ce 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/citrate-versus-heparin-anticoagulation-during-crrt-with-mg350-hemoadsorption-in-fd82283ab4495bfc 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-treatment-outcomes-of-pleural-effusion-and-empyema-thoracis-bbe452d5da9517d3 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/factors-associated-with-lymphoma-recurrence-following-autologous-stem-cell-trans-bcec6940d14004db 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phytochemical-dark-matter-unlocking-the-untapped-chemical-diversity-of-medicinal-341f859e1c659ac5 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oroxylin-a-loaded-microemulsion-gel-a-promising-approach-for-anti-gout-therapy-a-7d7fc2b7ca4b7e5b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/plant-protein-microcapsules-for-nutraceutical-delivery-3b5fb647884c6359 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/quality-control-evaluation-of-different-brands-of-paracetamol-tablets-available-c006a743158b4b8c 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-correlation-between-the-severity-of-periodontitis-and-alzheimer-s-disea-48dd87cd72f1219b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/predicting-hemorrhagic-transformation-in-acute-ischemic-stroke-using-a-machine-l-38c2eae679ddb40b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-adding-gait-retraining-with-visual-feedback-to-resistance-balance-tra-1e167cbe3a805226 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/low-intensity-transcranial-electrical-stimulation-for-schizophrenia-a-triple-bli-e89af31c21e6c675 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-indications-and-determinants-of-field-of-view-selection-in-cone-beam-co-502e081a3fdf5538 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systemic-antibiotic-use-in-paediatric-odontogenic-infections-a-systematic-review-c467c59adf57184a 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/asymmetrical-bilateral-ureteral-duplication-a-cadaveric-case-report-illustrating-c69d3b4b913c453c 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/minimally-invasive-needle-arthroscopy-versus-conventional-arthroscopy-for-treatm-6fc5da0721eea615 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-companion-based-emotional-care-on-treatment-adherence-and-physiologic-51e959a4f87a7502 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/self-medication-among-pharmacy-technician-students-in-offa-nigeria-implications-5a745c612e38bddc 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/school-based-hygiene-intervention-to-prevent-helicobacter-pylori-infection-among-fb3eeb7f9942f557 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-a-smartphone-intervention-to-improve-hiv-prevention-and-care-outcomes-bd52996327321260 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/perceived-risk-of-cardiovascular-diseases-in-the-italian-population-a-baseline-c-1d63a7e202355d83 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-progressive-muscle-relaxation-training-in-post-traumatic-stress-diso-96a07acf7bd3c00a 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/potentially-inappropriate-medication-use-and-selected-drug-related-problems-amon-7b866e4c8c711bc1 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-concomitant-grade-i-degenerative-spondylolisthesis-on-clinical-and-rad-b3aa13f3b078fc7d 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/giddy-up-can-we-reduce-dropouts-in-a-discrete-choice-experiment-by-including-an-19993b5edd03242d 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/partial-mock-up-guided-rehabilitation-of-severe-tooth-wear-a-clinical-technique-ff05853f0fa3d358 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/care-gaps-following-newly-detected-dipstick-proteinuria-in-treated-hypertension-f6038d0fa7cd35f9 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systematic-benchmarking-of-evaluation-paradigms-safety-boundaries-and-clinical-r-b9d82694e09b72b9 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/thermodynamic-molecular-interdependencies-and-causal-determinants-governing-phar-10f10c771e7ee1bf 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-hitop-and-clinical-staging-a-developmental-framework-for-multidimens-b476eea2461db944 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/long-term-clinical-outcomes-of-a-hydrofilic-extended-depth-of-focus-intraocular-e572e5d1e90d64cf 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-impact-of-antihypertensive-de-escalation-a-secondary-analysis-of-systolic-bl-aa5240ab42a1ed19 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sertraline-e9737e737cba8913 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/salicylates-50f1ce7783b22311 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nitrous-oxide-6c11750953e77a2e 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/metamfetamine-123bf776ae9e5ebd 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lithium-paracetamol-d20337e1f8385dbe 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dicycloverine-0773d3ef428c7525 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diamorphine-95e6194fbd91bf71 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/daptomycin-3c236bfd74a7ae7e 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amlodipine-propranolol-fa0af215e5fdd4ed 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/deciphering-the-interaction-landscape-of-ndm-1-with-a-novel-lactam-based-inhibit-50512220ed8c509d 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/piper-betle-essential-oil-enhances-antibiotic-susceptibility-and-attenuates-quor-de37c35cede42ef5 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-a-card-game-based-intervention-in-alleviating-preoperative-anxi-15dbe051b2ff20ba 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/micellar-systems-with-hydrophobic-core-stabilized-polyethyleneimine-enabling-tim-687784dcfb17eba7 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-based-smoke-removal-in-robotic-urooncologic-surgery-a-clinical-pilot-study-4053782a128a77b3 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/conceptual-growth-curves-of-oropharyngeal-soft-tissues-and-craniofacial-skeletal-d450161164c51a8c 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/brief-cognitive-behavioral-therapy-for-suicide-prevention-among-racially-and-eth-0036a6580553d84c 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nature-based-interventions-in-practice-a-scoping-review-of-social-work-literatur-37b90182012c11fc 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systematic-review-and-network-meta-analysis-for-the-2026-update-of-the-evidence-a7b29411b4772e4d 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adverse-event-risks-and-prognostic-factors-associated-with-endoscopic-laryngopha-70d33963692fe251 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-low-level-laser-therapy-in-the-rehabilitation-of-knee-meniscus-d2ca201f02c9cb87 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-microvascular-footprint-of-lupus-nailfold-capillaroscopy-findings-in-egyptia-9a72384817265498 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integration-of-early-palliative-care-in-cancer-treatment-a-meta-analysis-of-39-r-2e2b33d95289c590 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/outcomes-of-surgical-intervention-in-retinal-detachment-in-stickler-syndrome-a-s-d4130766d2a7171b 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysis-of-brain-volumetry-and-functional-connectivity-during-resting-state-in-eb430aad5af9a35e 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/accelerated-tms-is-associated-with-changes-of-subgenual-cingulate-default-mode-n-8dc272ce8dd99d43 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/case-based-pharmacotherapeutic-learning-structured-around-the-prescribing-optimi-58d9c0cc03a64972 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/genetically-supported-targets-and-drug-repurposing-for-sleep-disorders-a-mendeli-996bda825dee064a 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-diagnostic-accuracy-to-clinical-utility-methodological-considerations-on-co-9df4003c012e3774 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-continuing-or-withholding-angiotensin-axis-blockers-prior-to-elective-595c845626078b7c 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/operationalization-of-the-african-medicines-agency-retrospective-evaluation-of-t-159de1ff28a10a52 2026-09-19T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-2f48405acfbfdc68 2026-09-18T23:59:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34b 2026-09-18T23:43:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/anthropic-is-operating-a-lab-that-conducts-biology-experiments-c2a67f2be86581ad 2026-09-18T23:13:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-e56809726c192c50 2026-09-18T23:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/omnideployment-the-future-of-pharmaceutical-commercialization-1f60f5db440b5bd7 2026-09-18T22:53:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-765166c7c178a647 2026-09-18T22:51:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/marshall-raises-alarm-over-glp-1-drug-supply-chain-94e3f4e2dce5d374 2026-09-18T22:46:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-4d1ca8ecf7dd9852 2026-09-18T22:38:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-9706597300d79daa 2026-09-18T22:35:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/hundreds-of-drugs-and-devices-approved-by-the-fda-are-missing-key-safety-studies-c92efb17bc851318 2026-09-18T22:32:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech-1e7372ba15a5f576 2026-09-18T22:28:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-examines-use-of-testosterone-prescriptions-for-menopause-c359720bb3a5c490 2026-09-18T22:26:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-028baa1e5af406d9 2026-09-18T22:22:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/virtual-biotech-company-puts-37-000-ai-agents-to-work-on-drug-discovery-0ab60bbf89b1de5e 2026-09-18T22:11:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/consulta-publica-requerimientos-tecnicos-administrativos-cb077950f600650a 2026-09-18T21:42:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/trxb-ipo-news-autoimmune-and-inflammatory-diseases-biotech-trex-bio-files-for-a-f91025b93b89cfb7 2026-09-18T21:39:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mizuho-s-jared-holz-data-doesn-t-show-a-strong-link-between-biotech-and-interest-55a37aa704a9bd07 2026-09-18T21:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-eli-lilly-breast-cancer-drug-combination-19d02ea866c7101b 2026-09-18T21:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-eli-lilly-breast-cancer-drug-combination-inluriyo-and-verzenio-2dc2e9a373a655fe 2026-09-18T21:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-throughput-aav-affinity-chromatography-screening-99009d14e786d1a1 2026-09-18T21:27:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/mirum-pharmaceuticals-falls-7-1-as-investors-appear-to-reassess-near-term-biotec-1d2cd1c93d265677 2026-09-18T21:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/white-house-extends-mfn-pricing-to-every-state-medicaid-program-46597a1d0cb97779 2026-09-18T21:19:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/retension-pharmaceuticals-clinical-stage-biopharma-for-hypertension-files-for-na-500bd9025ece2e61 2026-09-18T21:18:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-levacetylleucine-to-treat-ataxia-in-adult-pediatric-patients-with-a-d2e36698305e5a0e 2026-09-18T21:04:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-moderna-s-mrna-seasonal-flu-vaccine-b34d6e90abb860ab 2026-09-18T21:04:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/moleculin-biotech-disclosed-failure-to-satisfy-a-continued-listing-rule-or-stand-e8243697e82aa9a0 2026-09-18T21:03:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-fund-tied-to-teva-nyse-teva-director-plans-share-sale-2f066a6ddabc3077 2026-09-18T21:00:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/lakewood-amedex-announces-irb-approval-to-initiate-phase-2a-clinical-trial-of-nu-a1ad04495c6460fd 2026-09-18T20:59:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/lakewood-amedex-announces-irb-approval-to-initiate-phase-2a-clinical-trial-of-nu-eb20b4f8617ed6ba 2026-09-18T20:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-launches-pilot-program-to-speed-early-clinical-trials-e9db1ce137d303a4 2026-09-18T20:52:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-fayuvi-pharmexec-a23663528c3d4358 2026-09-18T20:45:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/saved-by-wife-s-cpr-bay-area-survivor-leads-heart-walk-to-build-nation-of-lifesa-ec36780d62d0d2bd 2026-09-18T20:43:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-biotech-ipo-window-keeps-opening-09264c228e834eae 2026-09-18T20:23:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-928c95dbf2da8b91 2026-09-18T20:10:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-this-biotech-just-erased-its-one-day-50-pop-69c3a9008e5f3dad 2026-09-18T20:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amneal-announces-fda-approval-and-launch-of-lanreotide-injection-717b592a47d5528f 2026-09-18T20:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-taps-anthropic-s-claude-to-speed-drug-discovery-6bb9050bfd33342b 2026-09-18T19:57:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-to-announce-all-50-states-joining-medicaid-drug-pricing-model-7e1e4bb1b9a04278 2026-09-18T19:46:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-to-announce-all-50-states-joining-medicaid-drug-pricing-model-843f8dad1754e2e8 2026-09-18T19:41:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/vantuil-pereira-e-reconduzido-a-decania-do-centro-de-filosofia-e-ciencias-humana-b4aa1e29c3408934 2026-09-18T19:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-may-kill-us-all-but-biotech-is-the-bigger-threat-to-stocks-cabot-street-check-f6aae46ec1c2910c 2026-09-18T19:36:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-adds-capital-markets-veteran-as-cfo-while-advancing-bitac-on-a0783c107c82669c 2026-09-18T19:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/japan-approves-t-dxd-combo-and-dato-dxd-for-first-line-metastatic-breast-cancer-2e49898c769c590a 2026-09-18T19:11:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/steve-marshall-offers-warning-to-rubio-about-chinese-national-security-threat-in-f029735522effd19 2026-09-18T19:05:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-plans-to-transform-3m-biotech-sector-into-522b-powerhouse-by-2030-f0565aa05697d5e2 2026-09-18T19:05:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/kailera-therapeutics-hold-due-to-need-for-progress-on-weight-loss-differentiatio-ae1f507693f6964a 2026-09-18T19:02:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/insilico-medicine-sehk-3696-advances-rentosertib-into-phase-3-trials-df912cbea33fd048 2026-09-18T18:45:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-ibtrozi-label-update-with-49-7-month-dor-in-ros1-nsclc-5fd4f5cd632ba7ac 2026-09-18T18:44:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-issues-food-safety-advisory-for-ganpati-mahaprasad-5cb211e0958c2aff 2026-09-18T18:42:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-approves-inluriyo-in-combination-with-verzenio-for-adults-with-er-her2-e-26acb00ee3b4851e 2026-09-18T18:41:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-seizes-593kg-expired-ghee-in-akola-959cf32ca802af8a 2026-09-18T18:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-personalised-medicine-by-using-an-advanced-point-of-care-tool-for-8b4326c6c0ba25cc 2026-09-18T18:26:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-future-of-alcl-novel-therapies-origins-bio-markers-and-mechanism-27cd89b4f8f7af8c 2026-09-18T18:26:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-reducing-the-impact-of-major-environmental-challenges-on-mental-h-31bc826d56d240c6 2026-09-18T18:26:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-transforming-into-a-sustainable-european-pharmaceutical-sector-28dd3912c72b3695 2026-09-18T18:26:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-understanding-predicting-and-treating-depression-in-pregnancy-to-3a9a37311258eec2 2026-09-18T18:26:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/xene-stock-drops-30-on-phase-3-trial-halt-price-to-sales-ratio-signals-market-sk-7c05d70fbabc3156 2026-09-18T18:25:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-s-3-95-million-fayuvi-secures-first-ever-fda-approval-for-sanfilippo-1aea3c06c9330b77 2026-09-18T18:22:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/genmab-stock-gains-as-petosemtamab-phase-3-start-and-strong-q2-figures-support-v-c1aa15b564b629fc 2026-09-18T18:20:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/palatin-technologies-inc-common-stock-nyse-ptn-share-price-ptn-stock-news-ptn-sh-b0999d2cb09b2ab1 2026-09-18T18:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-appoints-raju-willener-as-cfo-9709b95d0f9b3358 2026-09-18T18:03:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-this-biotech-stock-too-cheap-to-ignore-after-its-latest-pullback-91f5f5b430dc71f5 2026-09-18T18:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/first-drug-to-treat-alexander-disease-approved-by-the-fda-after-three-decades-of-34a9482c55fea16c 2026-09-18T17:55:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-legend-biotech-legn-undervalued-following-its-new-ceo-appointment-066eb92b1b6f57ca 2026-09-18T17:53:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/xenon-plunges-30-after-depression-trial-halt-abef9e9d0f20f74a 2026-09-18T17:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sahpra-reinforces-its-commitment-to-radiation-safety-at-iaea-general-conference-1042c5a1d277999b 2026-09-18T17:32:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-legend-biotech-legn-undervalued-following-its-new-ceo-appointment-a9f1a69f6fd68a4e 2026-09-18T17:30:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/pune-cockroaches-rat-droppings-found-in-new-poona-club-kitchen-fda-suspends-lice-2cb12354e9616079 2026-09-18T17:28:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-this-biotech-stock-too-cheap-to-ignore-after-its-latest-pullback-8a72dc88fe000b4e 2026-09-18T17:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/montana-opened-a-market-for-experimental-medicines-now-it-should-watch-who-shows-b84ace46a9df7e13 2026-09-18T17:14:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/pune-fda-seizes-adulterated-food-worth-rs-56-36-lakh-banned-gutkha-worth-rs-20-2-b25b754ddcb9cba2 2026-09-18T17:08:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/post-hoc-live-the-china-biotech-debate-goes-to-washington-601b5ca4af133974 2026-09-18T17:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agriculture-studies-networks-for-food-security-agri-net-jica-c3fe72a28b1dd90d 2026-09-18T17:04:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-grants-priority-review-to-azn-s-filing-for-rare-bone-disease-drug-284dec142f29d460 2026-09-18T17:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aard-investor-alert-aardvark-therapeutics-inc-securities-class-action-notice-con-b5a869d6fef920bf 2026-09-18T16:54:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-d48516f28aaf5220 2026-09-18T16:54:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/radar-st-84ce3e802a2d1e73 2026-09-18T16:52:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/umd-students-band-together-to-protect-birds-b1696d7be266e817 2026-09-18T16:50:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/big-lake-agrivoltaics-project-shows-promise-of-mixing-farming-solar-power-e943f5608c414bf6 2026-09-18T16:50:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/umd-engineers-building-brighter-futures-from-duluth-to-kenya-5875172bba4f6965 2026-09-18T16:49:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/hornets-are-sending-minnesotans-to-the-er-and-into-party-mode-3a7c2094446f40fc 2026-09-18T16:48:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-s-authoritarian-mindset-can-t-handle-dissent-from-his-appointees-0f72e70f2f17c74b 2026-09-18T16:48:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/glass-pumpkin-patch-at-the-arboretum-d02dfdd728c01c10 2026-09-18T16:48:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-ai-agents-satisfy-cgmp-documentation-requirements-609a4915047af303 2026-09-18T16:35:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/sol-gel-s-patidegib-gel-nears-key-milestone-with-completed-phase-3-gorlin-syndro-22fa92c124816b79 2026-09-18T16:33:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/dallas-clinical-research-unit-sponsor-overview-f49234afe6268753 2026-09-18T16:33:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/4-biotech-stocks-to-watch-as-potential-takeover-targets-471a060d652d759a 2026-09-18T16:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-ev-dose-is-not-what-it-seems-quantitative-mismatch-between-particle-number-f47a7c5a1a3284b4 2026-09-18T16:29:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/xene-files-nda-for-epilepsy-drug-falls-on-depression-studies-setback-d69eea09fb83040d 2026-09-18T16:22:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-false-attack-on-vivek-ramaswamy-raises-a-harder-question-who-hears-the-correct-740dd3f761e3a48c 2026-09-18T16:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/semi-mechanistic-joint-population-pharmacokinetic-modeling-of-the-novel-antitube-ebec18c2810c96c6 2026-09-18T16:02:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/mabxience-sandoz-partner-on-emicizumab-biosimilar-deal-a640a1a39a3338f8 2026-09-18T15:56:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-fund-84639908b0e2b140 2026-09-18T15:50:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-options-buzz-uthr-nmra-ewtx-904141373556fd38 2026-09-18T15:46:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/all-50-states-sign-up-for-trump-s-medicaid-most-favored-nation-plan-770767e418ae8a3a 2026-09-18T15:41:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/do-you-have-to-be-bilingual-to-participate-in-circle-u-activities-c8b706a758c482a8 2026-09-18T15:39:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/attorney-general-marshall-leads-coalition-alerts-national-security-council-to-ex-3be9dd83d1d6ace8 2026-09-18T15:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-expands-its-boston-footprint-with-new-research-center-61c8eaa9d2c59da9 2026-09-18T15:33:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/definium-trial-suggests-lsd-could-help-treat-anxiety-one-patient-meets-god-the-o-cb4c52a47721d100 2026-09-18T15:30:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/naver-s-venture-capital-arm-invests-in-u-s-ai-precision-medicine-startup-imprime-0a2754cf400de157 2026-09-18T15:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emirates-biotech-and-partner-launch-uae-organic-waste-to-biogas-pilot-7528d116c86d5b63 2026-09-18T15:24:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/refreshed-novo-corrals-3-new-early-stage-obesity-drugs-from-kallyope-40f3fb0496b9f73e 2026-09-18T15:23:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-circle-u-helped-me-define-my-career-path-81b7d487eea3e910 2026-09-18T15:21:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/m-a-roundup-lisata-therapeutics-acquires-marea-therapeutics-mabxience-enters-col-82f692d91f282f5e 2026-09-18T15:18:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-week-in-charts-gsk-s-china-deals-the-300m-ipo-club-and-selling-the-news-136aee8ad04163b2 2026-09-18T15:17:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/xenon-stock-reaction-is-overblown-analyst-00ea9c26fd548a87 2026-09-18T15:14:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-metabolic-disease-heterogeneity-definition-prevention-and-remissi-02382b733dd4e87c 2026-09-18T15:12:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-next-generation-therapeutics-for-vascular-diseases-3a4c8847c4d7458e 2026-09-18T15:11:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/addressing-the-treatment-gap-in-cannabis-use-disorder-ad222fb9336b9389 2026-09-18T15:09:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/david-oliwenstein-biopharma-s-confidential-trial-data-is-the-next-insider-tradin-503b6bc20674765a 2026-09-18T15:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-ai-biotech-and-personalization-are-reshaping-the-beauty-industry-by-2030-932bc402d6e4135f 2026-09-18T15:04:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-adrs-slip-in-us-trading-as-biotech-splits-5d79b846c95a7a75 2026-09-18T15:00:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/37-000-ai-agents-are-running-a-virtual-biotech-at-stanford-486a0da87125e24a 2026-09-18T14:52:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-highlights-new-real-world-data-supporting-the-effectiveness-of-vraylar-at-0a7b9d49f4f19d38 2026-09-18T14:50:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-buzz-rare-bayry-win-approvals-sion-cuts-jobs-gsk-deals-azn-rhhby-lead-a1a9090f97fd12fd 2026-09-18T14:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-sees-large-volume-increase-after-analyst-u-02e90aaa7ef82c7c 2026-09-18T14:42:34.000Z weekly 0.7